



HAL
open science

CEP290, a gene with many faces: mutation overview and presentation of CEP290base

Frauke Coppieters, Steve Lefever, Bart P. Leroy, Elfride Bw de Baere

► **To cite this version:**

Frauke Coppieters, Steve Lefever, Bart P. Leroy, Elfride Bw de Baere. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. *Human Mutation*, 2010, 31 (10), pp.1097. 10.1002/humu.21337 . hal-00563445

HAL Id: hal-00563445

<https://hal.science/hal-00563445>

Submitted on 5 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



CEP290, a gene with many faces: mutation overview and presentation of CEP290base

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0040.R1
Wiley - Manuscript type:	Mutation Update
Date Submitted by the Author:	18-Jun-2010
Complete List of Authors:	Coppieters, Frauke; Ghent University Hospital, Center for Medical Genetics Lefever, Steve; Ghent University Hospital, Center for Medical Genetics Leroy, Bart; Ghent University Hospital, Department of Ophthalmology; Ghent University Hospital, Center for Medical Genetics De Baere, Elfride; Ghent University Hospital, Center for Medical Genetics
Key Words:	CEP290, locus-specific database, genotype-phenotype correlations, modifiers, ciliary proteome



1
2 *CEP290*, a gene with many faces: mutation overview and presentation of
3
4
5 *CEP290base*
6
7
8
9

10
11 Frauke Coppieters^{1*}, Steve Lefever^{1*}, Bart P. Leroy^{1,2}, Elfride De Baere¹
12
13

Deleted: Jo Vandesompele¹.

14
15
16 ¹Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
17

18
19 ²Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium
20

21
22 *These two authors contributed equally to this work.
23
24
25
26

27 Address for Correspondence: Elfride De Baere, MD, PhD, Elfride.DeBaere@UGent.be, Center
28
29 for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B- 9000 Ghent, Belgium,
30
31 Phone: 32-9-332.5186 Fax: 32-9-332.6549.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Ciliopathies are an emerging group of disorders, caused by mutations in ciliary genes. One of the most intriguing disease genes associated with ciliopathies is *CEP290*, mutations in which cause a wide variety of distinct phenotypes, ranging from isolated blindness over Senior-Loken syndrome (SLS), nephronophthisis (NPHP), Joubert syndrome (related disorders) (JS[RD]), Bardet-Biedl syndrome (BBS) to the lethal Meckel-Grüber syndrome (MKS). Despite the identification of over 100 unique *CEP290* mutations, no clear genotype-phenotype correlations could yet be established and consequently the predictive power of a *CEP290*-related genotype remains limited. One of the challenges is a better understanding of second-site modifiers. In this respect, there is a growing interest in the potential modifying effects of variations in genes encoding other members of the ciliary proteome which interact with CEP290.

Here, we provide an overview of all *CEP290* mutations identified so far, with their associated phenotypes. To this end, we developed *CEP290base*, a locus-specific mutation database that links mutations with patients and their phenotypes (medgen.ugent.be/cep290base).

Key words: CEP290, locus-specific database, genotype-phenotype correlations, modifiers, ciliary proteome

Deleted: of

Deleted: n

Deleted: emerging

Deleted: other components of the ciliary proteome, possibly modifying phenotypes caused by mutations in interacting proteins

Deleted:

Deleted: For this purpose

Background

Cilia are highly conserved organelles that are essential for many cell types. Apart from their obvious role in motility and transport of fluids and particles over epithelial surfaces, they have numerous other functions such as signal transduction (Berbari et al., 2009). The extensive presence of cilia throughout the whole body might explain the wide range of phenotypes associated with mutations in genes encoding ciliary proteins (Gerdes et al., 2009; Nigg and Raff, 2009).

Deleted: exert

Deleted: reception and

One of the most intriguing disease genes associated with ciliopathies is *CEP290* ([MIM\[610142\]](#)), as the phenotypic spectrum of its mutations ranges from isolated blindness to the lethal Meckel-Grüber syndrome (MKS). The gene was initially identified as disease gene for Joubert syndrome (related disorders) (JS[RD]) and Senior-Loken syndrome (SLS) (Sayer et al., 2006; Valente et al., 2006). Within a few years, Leber Congenital Amaurosis (LCA), MKS and Bardet-Biedl syndrome (BBS) expanded the list of partially overlapping yet distinct disorders caused by *CEP290* mutations (den Hollander et al., 2006; Baala et al., 2007a; Leitch et al., 2008). Although these are essentially autosomal recessive (AR) monogenic diseases, epistatic effects of modifier alleles in additional ciliary genes should not be underestimated in the development of their phenotypes.

Deleted: other

The first clone corresponding with *CEP290*, *KIAA0373*, was identified through sequencing of 100 new cDNA clones from human brain cDNA libraries (Nagase et al., 1997). Three years later, Chen and Shou independently cloned *CEP290* as *3H11Ag*, encoding an antigen for the monoclonal antibody 3H11 which specifically recognizes cancer cells from various tissues (Chen and Shou, 2001). It was predicted that about 60% of the residues form coiled-coil (CC) structures

1
2 and that the protein has four potential dimeric CC regions. In addition, the protein displays high
3
4 similarity to myosin among different species and was predicted to have a partial structural
5
6 maintenance of chromosomes (SMC) conserved domain. Several predicted motifs suggested
7
8 potential modifications such as N-glycosylation, tyrosine sulfation and phosphorylation (Guo et
9
10 al., 2004). In 2003, Andersen and colleagues detected the KIAA0373 gene product in human
11
12 centrosomes following mass-spectrometry-based proteomic analysis. The protein was called
13
14 Cep290 according to its centrosomal location and approximate relative molecular mass, and was
15
16 predicted to contain nine CCs (Andersen et al., 2003). Upon the identification of *CEP290* as a
17
18 novel disease gene for JS, *CEP290* was further characterized. Analysis of the deduced amino acid
19
20 (AA) sequence revealed 13 putative CC domains, a region with homology to SMC chromosomal
21
22 segregation ATPases, a bipartite nuclear localization signal, six RepA/Rep+ protein KID motifs,
23
24 three tropomyosin homology domains and an ATP/GTP binding site motif A (Sayer et al., 2006).
25
26 The *CEP290* gene as currently annotated, spans 54 exons with the coding region starting in exon
27
28 2 ([NM_025114.3](#)). Given the broad allelic spectrum, the complexity of associated phenotypes
29
30 and the presumed influence of modifier genes, the establishment of genotype-phenotype
31
32 correlations poses a major challenge.

Deleted: and a myosin-like domain

Deleted: the

Deleted: protein

Deleted: CEP290

33 34 Variants in *CEP290*

35 36 37 Mutations

38
39 So far, 112 distinct mutations have been identified ([Figure 1, Supp. Table S1, NM_025114.3](#)).
40
41
42 The vast majority of *CEP290* mutations are truncating, with 40 nonsense and 48 frameshift
43
44 mutations reported so far. All frameshifts are caused by small deletions or insertions, with the
45
46 exception of two indels (c.381_382delinsT and c.5865_5867delinsGG). Three deletions and one
47
48 duplication directly lead to a premature termination codon (PTC) without the incorporation of
49

Deleted: 111

Deleted: Table 1

Deleted: 39

novel AAs (c.1550del, c.2906dup, c.3175del and c.5046del). Taking into account the position of the PTC relative to the ultimate 3' exon-exon junction, 85 truncating mutations are assumed to undergo nonsense mediated decay (NMD) (Nagy and Maquat, 1998). However, the p.Arg151X mutation was shown to result in alternative transcripts, lacking exon 7 or both exon 7 and 8, leaving the open reading frame intact (Littink et al., 2010). Three truncating mutations located in the last exon are expected to escape NMD and render a protein product (c.7318_7321dup, c.7341 dup and c.7366_7369del).

Deleted: ,

Deleted: and c.2906dup

Deleted: -most

Deleted: 84

Deleted: be

Deleted: In contrast, three

Deleted: to

In addition to the 88 truncating mutations caused by small variations, a large heterozygous deletion was recently identified in a patient with cerebello-oculo-renal syndrome (CORS). The deleted region spanned 76,844 bp at the genomic level, encompassing the last 13 coding exons of *CEP290*, the entire *C12orf29* gene and part of the *C12orf50* gene (CEP290:c.5709+2352_54_C12orf50:c.290-1375_77del) (Travaglini et al., 2009).

Deleted: 87

Deleted: following copy number profiling of the *CEP290* gene in nine patients carrying a single *CEP290* mutated allele (4 CORS, 1 MKS and 4 LCA)

The remaining 23 mutations comprise 3 missense mutations and 20 mutations predicted to influence splicing. Of the latter, 12 mutations affect consensus donor or acceptor splice sites, whereas three mutations are located within 20 nucleotides surrounding the exon. The first two, c.103-13_103-18del and c.6271-8T>G, were considered to be likely pathogenic because they decreased the scores of the normal splice sites and because they are absent in more than 115 control individuals (Tory et al., 2007). The third one, c.1711+5A>G, was presumed to result in both abnormally and normally spliced transcripts (Perrault et al., 2007). Splice site prediction scores, however, remain unchanged for this variant (Alamut v.1.5, data not shown). In addition, an aberrant splicing pattern was predicted for the c.1824G>A mutation affecting the last nucleotide of exon 18 (Coppieters et al., 2010). Surprisingly, the most recurrent mutation, c.2991+1655A>G, represents a deep intronic mutation. It creates a strong splice donor site that

Deleted: three

Deleted: (Table 1)

Deleted: reported

Deleted: probably

1
2 results in the insertion of a 128-bp cryptic exon between exons 26 and 27, thereby leading to a
3
4 PTC immediately downstream of exon 26 (p.Cys998X) (den Hollander et al., 2006). Apart from
5
6 these 17 substitutions, two deletions and one indel overspan an intron-exon boundary (c.2218-
7
8 4_2222del, c.2218-15_2220del and c.3310-1_3310delinsAA).

9
10
11 So far, only three missense variants have been described with a probable pathogenic effect (see
12
13 “Polymorphisms and unclassified variants” for other missense variants). Two affect the start
14
15 codon (c.1A>G and c.2T>A) whereas the third, p.Trp7Cys, affects a highly conserved AA and is
16
17 predicted to disrupt protein function according to SIFT, PolyPhen and Grantham matrix.
18
19 However, the mutant protein was correctly localized at centrosomes in mouse inner medullary
20
21 collecting duct (IMCD-3) cells, suggesting a pathogenic mechanism different from
22
23 mislocalization (Valente et al., 2006).

24
25 Interestingly, some mutations cluster in the same region or even codon, suggesting the existence
26
27 of mutation hotspots. In nine coding regions, two or more mutations arose either with a different
28
29 effect on protein level (start codon; c.381-387; c.1859-1862; c.3175-3176; c.4965-4966; c.5515-
30
31 5537; c.5865-5867; c.6869-6870) or with an identical predicted protein effect (c.4114-4116;
32
33 c.4962-4966). In addition, one donor and three acceptor splice sites displayed more than one
34
35 mutation (c.180+1G>T and c.180+2T>A; c.2218-2A>C, c.2218-4_2222del and c.2218-
36
37 15_2220del; c.3104-1G>A and c.3104-2A>G; c.3310-1_3310delinsAA and c.3310-1G>C). In
38
39 general, mutations are scattered throughout the protein, with some clustering in CCs III, XI and
40
41 XII (Figure 1). Coiled-coils might be involved in the overall conformation of CEP290. Therefore,
42
43 mutations in them might affect the accessibility of interacting proteins (Schafer et al., 2008).
44
45

Deleted: at the N-terminus of the protein. This change

Deleted: affect

Deleted: , but

Deleted: murine

Deleted: than

Deleted: _382delinsT, c.384_385del and c.384_387del

Deleted: _

Deleted: del and c.1860_1861del

Deleted: dup, c.3175del and c.

Deleted: del

Deleted: _4966del and c.4966G>T

Deleted: _5518del and c.5519_

Deleted: del

Deleted: _

Deleted: delinsGG and c.5866G>T

Deleted: del and c.

Deleted: del

Deleted: _4115del and c.4115_

Deleted: del

Deleted: _4963del and c.4965_

Deleted: del

Deleted: Mutations located in the SMC1-like domain might influence intraflagellar protein trafficking (Chang et al., 2006).

1
2 A total of 83 mutations are unique whereas 26 mutations have been reported in less than 10
3 families (Supp. Table S1). A few other mutations occurred multiple times and might even
4 represent founder mutations. The most recurrent one is c.2991+1655A>G. In northwestern
5 Europe, this mutation occurs in up to 26% of all LCA cases (den Hollander et al., 2006; Perrault
6 et al., 2007; Coppieters et al., 2010). In Southern Europe, Korea, Southern India and Saudi-
7 Arabia, however, c.2991+1655A>G has a significantly lower prevalence (Simonelli et al., 2007;
8 Vallespin et al., 2007; Seong et al., 2008; Li et al., 2009; Sundaresan et al., 2009). The second-
9 most frequent mutation, p.Lys1575X, was so far only reported in probands originating from
10 France (Lille) and northern Belgium (Brancati et al., 2007; Perrault et al., 2007; Coppieters et al.,
11 2010). Haplotype analysis in seven non-consanguineous families revealed a common intragenic
12 allele but distinct extragenic haplotypes, suggesting an ancient mutation (Perrault et al., 2007).
13 For p.Ala1832ProfsX19, allele sharing analysis in two families with MKS originating from
14 Kosovo and Kosovo-Albania was in favor of a common founder haplotype encompassing
15 approximately 3 Mb (Frank et al., 2008). In contrast, different haplotypes in two MKS families of
16 Tunisian and French origin point to a mutation hotspot for p.Asp128GlufsX34 (Baala et al.,
17 2007a). All mutations segregated in the parents (as far as this could be assessed), with the
18 exception of p.Gln2111X, which was reported to arise *de novo* in a patient with CORS (Sayer et
19 al., 2006).

20
21
22
23
24
25
26
27
28
29
30 In 18 patients, only one mutation was identified. This might be due to an inability of standard
31 PCR-based techniques to identify mutations such as deep intronic variants, large genomic
32 rearrangements or regulatory mutations located in promoter or enhancer/silencer elements. On
33 the other hand, the heterozygous *CEP290* mutation might represent a modifying allele,
34 potentially influencing the clinical expression of two AR mutations in another ciliary gene.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: 79

Deleted: 29

Deleted: Table 1

Deleted: mutation

Deleted: this mutation

Deleted: been described to have

Deleted: in LCA

Deleted: Contrary to the third-most frequent mutation p.Gly1890X that was found in 11 families worldwide, t

Deleted: North

Deleted: of the latter

Deleted: recurrent

Deleted: rather than a founder effect

Deleted: could be

Deleted: recessive

1
2 Similar arguments could also apply for five families with isolated NPHP in which no mutations
3
4 could be identified at all, despite linkage to a region containing *CEP290* (Helou et al., 2007).

Deleted: These

5
6 Alternatively, another as yet unidentified NPHP gene could segregate in linkage disequilibrium
7
8 with *CEP290* in these families.

Deleted: Again

10 Polymorphisms and unclassified variants

11
12 Several polymorphisms have been described in *CEP290*, for which we refer to dbSNP
13
14 (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and Brancati and colleagues (Brancati et al., 2007).

Deleted: in

15
16 They were predicted not to alter splicing patterns or to impair protein function, and/or were
17
18 present in over 2% of parents of affected individuals (Brancati et al., 2007). In addition, the

19
20 pathogenic potential of some variants is indefinite (Supp. Table S2). Indeed, for several missense
21
22 variants, *in silico* predictions are not conclusive (PolyPhen, SIFT and Grantham matrix). The first

Deleted: Table 2

Deleted: F

23
24 one is p.Asp664Gly. Despite the identification of this variant in a heterozygous state in a patient

25
26 with JS and renal involvement, p.Asp664Gly also occurred in a healthy parent of another family,

27
28 but not in his affected child (Brancati et al., 2007; Helou et al., 2007). Interestingly, Tory and

Deleted: four

29
30 colleagues screened this variant together with three other *CEP290* missense variants

31
32 (p.Glu277Gln, p.Lys838Glu and p.Arg1746Gln) in the context of modifier identification in the
33
34 following three cohorts: 1) 13 patients carrying *NPHP1* mutation(s) with neurological symptoms;

35
36 2) 77-82 patients carrying *NPHP1* mutation(s) without neurological symptoms and 3) 132-154

37
38 healthy control subjects. No significant difference in frequencies was found among these three

39
40 cohorts, however (Tory et al., 2007). Other missense variants of unknown significance are

41
42 p.Leu906Trp, p.Asn2228Lys, p.Ala1566Pro and p.Leu1694Pro (Brancati et al., 2007; Coppieters

43
44 et al., 2010). The latter two were found in two LCA patients, in compound heterozygosity with a

45
46 nonsense and splice site mutation, respectively, and segregated in healthy parents (Coppieters et

1
2 al., 2010). Two additional unclassified variants include in-frame deletions. A p.Glu1554del
3
4 variant segregated with p.Phe1950LeufsX15 in an LCA patient (Perrault et al., 2007), while a
5
6 heterozygous p.Lys2437del variant was identified in a patient with isolated NPHP originating
7
8 from consanguineous parents (Helou et al., 2007) ([Supp. Table S2](#)).

Deleted: Table 2

9 10 11 Mutation database

12
13
14 To provide a clear overview of all mutations and variants identified so far in *CEP290*, we
15
16 developed [CEP290base](http://medgen.ugent.be/cep290base) (medgen.ugent.be/cep290base). This [locus-specific mutation](#) database
17
18 uses a novel scheme in which both genomic and phenotypic data [are](#) available, providing the
19
20 possibility to link patients and their phenotypes to detailed variant information, and vice versa.
21
22 Information on variants can be retrieved using the Overview page or the Mutation Browser.

Deleted: the locus-specific mutation database

Deleted: is

23
24
25 The Overview page displays all unique variants following HGVS guidelines
26
27 (<http://www.hgvs.org/mutnomen>) (NM_025114.3), with their occurrence and links to dbSNP,
28
29 UniProt (<http://www.uniprot.org>) and OMIM
30
31 (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim>). In addition, a scaled graphical
32
33 representation of variants in the CEP290 protein is shown. Variants in the [O](#)verview or image are
34
35 linked to their variant-specific page which, if available, includes the protein domain (Sayer et al.,
36
37 2006), [as well as](#) the frequency in control individuals, the RNA effect and the estimate of
38
39 pathogenic probability (Stone, 2003). For truncating mutations, it is indicated whether mRNA
40
41 might be subjected to NMD (Nagy and Maquat, 1998), and for missense mutations, the Grantham
42
43 score is provided (Grantham, 1974). The database also links to SIFT (<http://sift.jcvi.org>) and
44
45 PolyPhen (<http://genetics.bwh.harvard.edu/pph>) prediction servers, using the CEP290 GI number
46
47 (109255233) and UniProt ID (O15078) for automated input, respectively. Links to NetGene2

Deleted: o

(<http://www.cbs.dtu.dk/services/NetGene2>) and the Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools/splice.html) are available for splice site mutations. A list of patients reported to carry the selected variant completes the variant-specific page. For each patient, information regarding disease, gender, age, origin, segregation and parental consanguinity is provided. Importantly, reported mutations are displayed using the nomenclature of the original publication, allowing easy retrieval of the variant from literature. If available, phenotypic information on ocular, renal, neurological and other signs appears by selecting the patient's ID. Disease calling was performed following the classification of Valente and coworkers, and is based on the involvement of different organ systems (Valente et al., 2008). Of note, these phenotypes might be incomplete due to factors such as a clinical investigation in an early disease stage.

Deleted:**Deleted:** specific**Deleted:** specific**Deleted:** who made a clear distinction between**Deleted:** n**Deleted:** early

The Mutation Browser enables custom querying. Both a quick and a more advanced search are possible. The quick search uses a selection of variant nomenclatures or patient IDs to list all patients carrying the selected variants, or all variants present in the selected patients. In the advanced search, different parameters can be set within and between three sections: variant, patient and source information. As in the quick search, the user has the choice between two output options: a mutation or patient list. Finally, users can submit novel or known variants they have identified.

Deleted: can be performed

In addition to the availability of phenotypic data in *CEP290base*, it also includes variants in other genes that co-occur with *CEP290* variants, thereby providing a unique opportunity to link modifiers to associated clinical manifestations (see “Epistatic effect of other components of the ciliary proteome”). The database is running on MySQL. PHP and JavaScript were used to develop the web-based interface.

Deleted: the novel database scheme of**Deleted:** the database**Deleted:** Mutation nomenclature is based on the NCBI RefSeq NM_025114, according to HGVS guidelines (<http://www.hgvs.org/mutnomen>).

Biological relevance

Expression

The original *KIAA0373* mRNA was found in kidney and ovary, and to a lesser extent in [human](#) thymus, prostate and testis tissue (Nagase et al., 1997). In addition, it was present in centrosomes from a human lymphoblastoid cell line ([KE-37](#)) (Andersen et al., 2003). The independently cloned *3H11Ag* mRNA was extensively [distributed in embryonic tissue and in different human](#) cancerous tissues, but not in corresponding normal human tissues (Chen and Shou, 2001). The 150 C-terminal AAs of 3H11Ag appeared to be responsible for nuclear translocation. In addition, cytoplasmic presence was also established (Guo et al., 2004). Consistent with the localization of the *KIAA0373* protein, CEP290 was found at centrosomes of both ciliated and non-ciliated cells (Chang et al., 2006; Sayer et al., 2006; Valente et al., 2006). This centrosomal localization of CEP290 is dynamic throughout the cell cycle, with redistribution to the cytosol starting in prometaphase (Sayer et al., 2006). During the interphase, two or four prominent spots were observed in the G1 and G2 phase. In the G0 phase, CEP290 was found on both the daughter and mother centriole, the latter from which the primary cilium is assembled (Tsang et al., 2008). Although the centrosomal localization is microtubule- and dynein-independent (Chang et al., 2006; Sayer et al., 2006), a major fraction of CEP290 is recruited to centriolar satellites along polymerized microtubules (Kim et al., 2008).

In the rod-dominated mouse retina, CEP290 was detected in the connecting cilia, and to a lesser extent in [the inner segments](#) (Chang et al., 2006; Sayer et al., 2006). Expression was also established in primate cone photoreceptors (Cideciyan et al., 2007). In olfactory sensory neurons, CEP290 [localizes](#) to dendritic knobs (McEwen et al., 2007). [A recent study on differential gene expression in the ventricular myocardium of newborn piglets identified CEP290 as being three-](#)

Deleted: human

Deleted: expressed

Deleted: is localized

Deleted: Similar to 3H11Ag, CEP290 showed both cytoplasmic and nuclear localization .

1
2 fold more enriched in the right compared with the left ventricle (Torrado et al., 2010). Knock-
3
4 down experiments in zebrafish using morpholinos caused defects reminiscent of JS, comprising
5
6 retinal, cerebellar and otic cavity developmental abnormalities as well as pronephric cyst
7
8 formation, ectopic brain tissue in the fourth ventricle and an abnormal mid-to-hindbrain region
9
10 associated with hydrocephalus (Sayer et al., 2006; Schafer et al., 2008). Alternatively spliced
11
12 transcripts/isoforms were identified by us in lymphocytes (data not shown) and observed as bands
13
14 of low molecular mass on immunoblot analysis in bovine retinal extracts (Chang et al., 2006).

Deleted: ¶

Deleted: antisense

Deleted: oligonucleotides

Deleted: being

16 17 Interaction with other (ciliary) proteins and function

18
19 Using a yeast two-hybrid screen and co-immunoprecipitation, Sayer and colleagues identified an
20
21 interaction between the N-terminal third of CEP290 (exons 2-21) and the C-terminal two thirds
22
23 of the Activation Transcription Factor 4 (ATF4) protein. Moreover, CEP290 was able to activate
24
25 ATF4-mediated transcription (Sayer et al., 2006). ATF4 has a protective function by regulating
26
27 the adaptation of cells to metabolic and oxidative stress, and is required for skeletal and lens
28
29 development, and haematopoiesis (Ameri and Harris, 2008). In addition, association with $G_{\gamma 13}$
30
31 and G_{olf} was identified in mouse olfactory epithelial tissue, suggesting a role of CEP290 in G
32
33 protein trafficking during olfactory perception (McEwen et al., 2007).

Deleted:

Deleted: of a human fetal brain expression library

Deleted: corresponding with

Deleted: can function both as a transcriptional activator and repressor. The protein also plays

Deleted: role

Deleted: in

Deleted: two components of the olfactory G protein,

Deleted: .

34
35 Moreover, CEP290 interacts with several centrosomal and ciliary proteins. Co-
36
37 immunoprecipitation experiments using mouse or bovine retinal extracts showed that CEP290 is
38
39 in complex with dynactin subunits p150^{Glued} and p50-dynamitin, kinesin subunit KIF3A, kinesin-
40
41 associated protein (KAP3), the pericentriolar components γ -tubulin and pericentrin, the centriolar
42
43 marker centrin, PCM1, ninein, SMC1, SMC3, retinitis pigmentosa GTPase regulator
44
45 (RPGR^{ORF15}) and RPGR-interacting protein 1 (RPGRIP1), but not with nucleophosmin, NPHP5
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: PCM1,

Deleted: pericentrin,

1
2 or RP1 (Chang et al., 2006). In mouse olfactory epithelial tissue, association with p150^{Glued},
3
4 KIF3A, RPGR^{ORF15} and γ -tubulin, but not BBS4 and IFT88, was also observed (McEwen et al.,
5
6 2007). Of note, a subsequent study showed that pericentrin, γ -tubulin and centrin do not exactly
7
8 co-localize with CEP290 (Kim et al., 2008).

Deleted: the pericentriolar components

Deleted: and

Deleted: ,

Deleted: the centriolar marker

10 Recently, a potential role for CEP290 in primary cilium assembly was established. Knock-down
11
12 of CEP290 using siRNAs in human retinal pigment epithelial cells caused a dramatic alteration in
13
14 the ability of cycling cells to assemble primary cilia on the one hand, and a disrupted migration of
15
16 mother centrioles to the cell cortex and primary cilia loss in quiescent cells on the other hand
17
18 (Kim et al., 2008; Tsang et al., 2008). This observation might – at least partially - be attributed to
19
20 the association of CEP290 with two proteins. First, CEP290 was found to be recruited to
21
22 centriolar satellites by PCM-1, which is required for the organization of the cytoplasmic
23
24 microtubule network. Both depletion and overexpression of CEP290 results in redistribution of
25
26 PCM-1, thereby possibly influencing the transport function of PCM-1 granules between the
27
28 cytosol and centrosome (Kim et al., 2008). In addition, CEP290 recruits Rab8a, a small GTPase
29
30 required for ciliary membrane elongation, at centrosomes and cilia (Kim et al., 2008; Tsang et al.,
31
32 2008). The interaction with Rab8a requires the CEP290 AAs 1208-1695 (Tsang et al., 2008). In
33
34 growing cells (not yet capable of ciliogenesis), the latter function of CEP290 is probably
35
36 inhibited through an interaction with CP110, which prevents CEP290-dependent Rab8a
37
38 ciliogenesis (Tsang et al., 2008). Truncating CEP290 mutants defined the following amino-
39
40 terminal regions necessary for and sufficient to bind CP110: AAs 1-366, AAs 221-366 and AAs
41
42 362-822. The binding region of CP110 consists of AAs 1-223, with major involvement of AAs
43
44 67-82 (Tsang et al., 2008).

Deleted: At f

Deleted: a major component of
centriolar satellites that

Deleted: and cooperates with the BBS
complex

Deleted: in cooperation with a core
complex of BBS proteins

1
2 Interestingly, several other CEP290-interacting proteins are also associated with ciliopathies
3
4 (Table 1). A first one is RPGR. Although a yeast two-hybrid screen could not identify a direct
5
6 interaction with CEP290, co-immunoprecipitation assays suggested complex formation and both
7
8 proteins co-localized in IMCD-3 cells and dissociated mouse rods (Chang et al., 2006). Mutations
9
10 in *RPGR* account for approximately 70-90% of X-linked retinitis pigmentosa (RP) and mainly
11
12 occur in isoforms containing the carboxy-terminal exon open reading frame 15 (*RPGR*^{ORF15}),
13
14 which are highly expressed in connecting cilia of photoreceptors (Hong et al., 2003; Shu et al.,
15
16 2007). In the *rd16* mouse (see “Animal models”), mutant CEP290 binds *RPGR*^{ORF15} more avidly,
17
18 leading to aggregation of *RPGR*^{ORF15} in the inner segments and redistribution of rhodopsin and
19
20 arrestin throughout the plasma membrane (Chang et al., 2006).

Deleted: Table 3

Deleted: photoreceptors

Deleted: subsequent

21
22 A second example of a CEP290-interacting protein also associated with ciliary disease is *NPHP5*,
23
24 which is associated with SLS. The protein binds calmodulin and is in complex with *RPGR*^{ORF15}
25
26 (Otto et al., 2005). Despite the absence of a complex between CEP290 and *NPHP5* in retinal
27
28 extracts (Chang et al., 2006), *NPHP5* was shown to specifically bind a region of CEP290
29
30 encompassing CCIII and part of the SMC homology domain (AAs 696 to 896) (Schafer et al.,
31
32 2008). Combined knock-down of both proteins in zebrafish embryos synergistically augmented
33
34 phenotypes seen in embryos treated with morpholinos for either *NPHP5* or *CEP290*. In *Xenopus*
35
36 *laevis*, expression of the *NPHP5*-binding domain of CEP290 caused substantial neural tube
37
38 closure defects that were similar to the effect of *NPHP5* knock-down. Moreover, co-expression
39
40 of the *NPHP5*-binding domain of CEP290 with *NPHP5* itself rescued the phenotype, supporting a
41
42 physical interaction between both proteins *in vivo* (Schafer et al., 2008).

Deleted: The *NPHP5* gene was first described as a disease gene for SLS, correlating well with its expression in connecting cilia and outer segments (OS) of photoreceptors and primary cilia of renal epithelial cells.

Deleted: the N-terminal

Deleted: Knock-down assays in zebrafish embryos of either *NPHP5* or *CEP290* leads to very similar neurological abnormalities and pronephric cysts, while combined knock-down of both proteins synergistically augmented these phenotypes.

43
44
45 Both *TMEM67* (MKS3) and *CC2D2A* are also CEP290-interacting proteins involved in disease.
46
47 Mutations in both genes may cause MKS, JS and COACH syndrome, which are all severe
48
49

Deleted: MKS3

Deleted: add to

Deleted: that are

Deleted: are

1 ciliopathies with multi-systemic involvement (Smith et al., 2006; Baala et al., 2007b; Gorden et
 2 al., 2008; Tallila et al., 2008; Brancati et al., 2009; Doherty et al., 2009). TMEM67 is involved in
 3 both ciliary structure/function and endoplasmic reticulum-associated degradation of surfactant
 4 protein C (Tammachote et al., 2009; Wang et al., 2009). Morpholino experiments in zebrafish
 5 revealed a strong genetic interaction between *cep290* and *Tmem67*, with more severe phenotypic
 6 effects following knock-down of both genes, compared with depletion of only one of both (Leitch
 7 et al., 2008). *CC2D2A* is presumed to act as a sensor for intracellular calcium and is part of the
 8 basal body complex from which the cilium is assembled, where it co-localizes with CEP290
 9 (Gorden et al., 2008; Tallila et al., 2008). The interaction between both proteins involves the 998
 10 N-terminal AAs of CC2D2A and a fragment of CEP290 containing CCs IV-VI (AAs 703-1130).
 11 A functional interaction was observed in the pronephros of *sentinel* zebrafish (Gorden et al.,
 12 2008).

Deleted: MKS3

Deleted: *mks3*

Deleted: proteins

Deleted: is expressed in many adult tissues, with high levels in prostate, pancreas, lung, retina, kidney and fetal brain and kidney (Gorden et al., 2008; Noor et al., 2008). It

Deleted: n

Deleted: internal

Deleted: ,

13 The involvement of CEP290 in the above-mentioned ciliary complexes strongly supports a role in
 14 ciliogenesis and ciliary trafficking. The (tissue-specific) access of its binding partners is possibly
 15 regulated by conformational changes of CEP290, since both the N-terminal (AAs 1-695) and C-
 16 terminal (AAs 1966-2479) domains are involved in homo- and heterodimeric interactions
 17 (Schafer et al., 2008).

Deleted: overall

37 Animal models

38 So far, two naturally occurring animal models are known with mutations in *cep290*: a pedigree of
 39 Abyssinian cats and the *rd16* mouse. Both models display AR progressive retinal degeneration,
 40 albeit with a different age-of-onset, possibly related to a differential effect of both distinct *cep290*
 41 mutations. Interestingly, no associated cerebellar or renal abnormalities are present in both

Deleted: animal

Deleted: Contrary to pleiotropic effects of *CEP290* in human

models (Chang et al., 2006; Menotti-Raymond et al., 2007). The cat and mouse orthologues show 92.1% and 87% AA sequence homology to human CEP290, respectively (Menotti-Raymond et al., 2007) (www.ensembl.org).

Deleted: Ensembl

The genetic defect for the Abyssinian cat retinal degeneration (rdAc) consists of a nucleotide substitution in intron 50 that creates a strong canonical splice donor site (IVS50+9T>G), resulting in a prolongation of exon 50 with 4bp, and a frameshift with a PTC three AAs downstream. The translated protein is truncated by 159 AAs, corresponding to the loss of the KIDV and KIDVI domains (Menotti-Raymond et al., 2007). The age of onset of the first ophthalmoscopic signs is highly variable, with 12-18 months of age in the majority of animals. Full-field flash electroretinography (ERG) at the age of eight months shows a reduction of mainly a-wave amplitudes, whereas reduced sensitivity of the pupillary light reflex is observed with disease progression. (Thompson et al., 2010; Narfstrom et al., 2009). Vacuolization and degeneration of membranes in the basal part of the rod outer segments (OS) in early stages of disease point to potential defects in protein transport through the connecting cilia (Menotti-Raymond et al., 2007).

Deleted: causal gene

Deleted:

Deleted: the inclusion of an additional 4 bp

Deleted: -insertion

Deleted: at the end of

In contrast to rdAC, the *rd16* mouse displays an early-onset retinal dystrophy, caused by a homozygous in-frame deletion of 897 bp (AAs 1599-1897) that covers the majority of the myosin-tail homology region. Early fundus examinations revealed white retinal vessels and large pigment patches, in addition to severely reduced ERG responses for both rods and cones. The mutation causes early progressive degeneration of the OS and reduction in thickness of the outer nuclear layer (Chang et al., 2006). In addition, considerable thickening of the inner nuclear and plexiform layer were observed in mid- and central retinal regions, together with an enlargement of nuclei of all retinal cell types (Cideciyan et al., 2007). Interestingly, *rd16* mice displayed severe early-onset olfactory dysfunction. Although the olfactory sensory neurons have

Deleted: m

Deleted: The age of onset of the first ophthalmoscopic signs is highly variable, with 12-18 months of age in the majority of animals

Deleted: a

Deleted: functions

Deleted: displayed

1 structurally intact cilia with correct localization of CEP290 to dendritic knobs, two components
 2 of the olfactory G protein that are in complex with CEP290, $G_{\gamma 13}$ and G_{olf} , were undetectable in
 3
 4
 5
 6 the cilia of *rd16* mice, suggesting a potential role for CEP290 in the regulation of olfactory G
 7
 8 protein trafficking (McEwen et al., 2007).
 9

Deleted: ACIII, CNGA2, and different G protein-coupled olfactory receptors

Deleted: . These data suggest

Deleted: into cilia

10 Both models offer interesting opportunities for *in vivo* research on CEP290 function and
 11 therapeutic intervention. The progressive nature of retinal disease in *rd16* mice resembles human
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Deleted: preceding

Clinical and diagnostic relevance

CEP290-linked phenotypes

Leber Congenital Amaurosis (LCA)

34 Leber Congenital Amaurosis (LCA, MIM[204000]) is the earliest and most severe form of all
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Deleted: In general, LCA is inherited in an AR manner.

Deleted: approximately

Deleted: causal

Deleted: the initial

1
2 unrelated LCA patients revealed its presence in 16 additional probands (21%), suggesting a major
3 involvement of *CEP290* in LCA (den Hollander et al., 2006). Subsequent studies corroborate that
4
5 involvement of *CEP290* in LCA (den Hollander et al., 2006). Subsequent studies corroborate that
6
7 *CEP290* mutations are highly recurrent in Northwestern Europe (Perrault et al., 2007; Coppieters
8 et al., 2010), but contribute to only a minor part of LCA in Italy, Saudi Arabia, Spain, Southern
9 India and Korea (targeted screening of c.2991+1655A>G in the latter three populations)
10 (Simonelli et al., 2007; Vallespin et al., 2007; Seong et al., 2008; Li et al., 2009; Sundaresan et
11 al., 2009). Interestingly, c.2991+1655A>G was not identified in 126 Spanish patients with early-
12 onset RP, suggesting specificity of this mutation for LCA (Vallespin et al., 2007).
13
14
15
16
17

Deleted: mainly originating from Northern Europe and Canada,

Deleted:

Deleted: indeed

Deleted: with a

18
19 The *CEP290*-related phenotype consists of a severe cone-rod type retinal dystrophy (Perrault et
20 al., 2007), with best-corrected visual acuity of counting fingers or worse in the majority of cases
21 (Walia et al., 2010). Early fundus changes include white dots or a marbled or salt and pepper
22 aspect, and progress to midperipheral nummular or spicular pigmentation (Littink et al., 2010;
23 den Hollander et al., 2006; Perrault et al., 2007; Coppieters et al., 2010). A detailed study of the
24 retinal architecture of human *CEP290*-mutant retinas identified profound retinal remodeling in
25 the peripheral rod-rich regions, which was characterized by thickening of inner retinal layers. In
26 the cone-rich foveal region, however, no clear alterations were observed. This difference in rod
27 and cone degeneration may point to a distinct function of *CEP290* in both cell types (Cideciyan et
28 al., 2007). Spectral-domain optical coherence tomography confirmed preservation of the outer
29 nuclear layer in the central macula, with distorted inner retina (Pasadhika et al., 2009). No
30 abnormalities were seen in visual brain pathway anatomy (Cideciyan et al., 2007). Apart from the
31 ocular phenotype, neurological involvement (mental retardation [MR] or autism) was observed in
32 approximately 11-33% of cases with *CEP290*-related LCA, which is more frequent than in
33 patients with mutations in other LCA genes (Hanein et al., 2004; Perrault et al., 2007; Coppieters
34 et al., 2010). A detailed study of the retinal architecture of human *CEP290*-mutant retinas identified profound retinal remodeling in
35 the peripheral rod-rich regions, which was characterized by thickening of inner retinal layers. In
36 the cone-rich foveal region, however, no clear alterations were observed. This difference in rod
37 and cone degeneration may point to a distinct function of *CEP290* in both cell types (Cideciyan et
38 al., 2007). Spectral-domain optical coherence tomography confirmed preservation of the outer
39 nuclear layer in the central macula, with distorted inner retina (Pasadhika et al., 2009). No
40 abnormalities were seen in visual brain pathway anatomy (Cideciyan et al., 2007). Apart from the
41 ocular phenotype, neurological involvement (mental retardation [MR] or autism) was observed in
42 approximately 11-33% of cases with *CEP290*-related LCA, which is more frequent than in
43 patients with mutations in other LCA genes (Hanein et al., 2004; Perrault et al., 2007; Coppieters
44 et al., 2010). A detailed study of the retinal architecture of human *CEP290*-mutant retinas identified profound retinal remodeling in
45 the peripheral rod-rich regions, which was characterized by thickening of inner retinal layers. In
46 the cone-rich foveal region, however, no clear alterations were observed. This difference in rod
47 and cone degeneration may point to a distinct function of *CEP290* in both cell types (Cideciyan et
48 al., 2007). Spectral-domain optical coherence tomography confirmed preservation of the outer
49 nuclear layer in the central macula, with distorted inner retina (Pasadhika et al., 2009). No
50 abnormalities were seen in visual brain pathway anatomy (Cideciyan et al., 2007). Apart from the
51 ocular phenotype, neurological involvement (mental retardation [MR] or autism) was observed in
52 approximately 11-33% of cases with *CEP290*-related LCA, which is more frequent than in
53 patients with mutations in other LCA genes (Hanein et al., 2004; Perrault et al., 2007; Coppieters
54 et al., 2010). A detailed study of the retinal architecture of human *CEP290*-mutant retinas identified profound retinal remodeling in
55 the peripheral rod-rich regions, which was characterized by thickening of inner retinal layers. In
56 the cone-rich foveal region, however, no clear alterations were observed. This difference in rod
57 and cone degeneration may point to a distinct function of *CEP290* in both cell types (Cideciyan et
58 al., 2007). Spectral-domain optical coherence tomography confirmed preservation of the outer
59 nuclear layer in the central macula, with distorted inner retina (Pasadhika et al., 2009). No
60 abnormalities were seen in visual brain pathway anatomy (Cideciyan et al., 2007). Apart from the
ocular phenotype, neurological involvement (mental retardation [MR] or autism) was observed in
approximately 11-33% of cases with *CEP290*-related LCA, which is more frequent than in
patients with mutations in other LCA genes (Hanein et al., 2004; Perrault et al., 2007; Coppieters

Deleted: abnormal expansion

Deleted: degeneration or thinning was

Deleted: n

Deleted: r

Deleted: area

Deleted: in six out of seven additional patients

Deleted: 5

et al., 2010). Four probands presented with either (transitory) hypotonia or ataxia (Perrault et al., 2007). Interestingly, some patients displayed signs suggestive for involvement of other ciliary processes. One patient presented with recurrent otitis media (Coppieters et al., 2010), and LCA patients homozygous for c.2991+1655A>G exhibited severe olfactory dysfunction, whereas mild to severe microsmia was observed in heterozygous carriers (McEwen et al., 2007). Obviously, MR, autism, ataxia and hypotonia may be signs of the mild end of the clinical spectrum of systemic phenotypes related to CEP290 rather than of true LCA as isolated retinal disease.

Nephronophthisis (NPHP) and Senior-Loken syndrome (SLS)

Nephronophthisis (NPHP, MIM[256100]) is the most frequent genetic cause for end-stage renal disease (ESRD) in the first three decades of life. Infantile, juvenile and adolescent forms have been described. Key histology findings are tubulointerstitial fibrosis, tubular atrophy, tubular dilatation and cyst formation. Renal ultrasound (US) reveals increased cortical echogenicity, loss of corticomedullary differentiation and corticomedullary cysts (Salomon et al., 2009; Simms et al., 2009). In 10-15% of cases, juvenile NPHP is accompanied by retinal involvement, which is called Senior-Loken syndrome (SLS, MIM[266900]). Based on the degree of retinal degeneration, both early-onset and late-onset types have been described. NPHP and SLS are AR disorders. So far, nine genes are known to cause NPHP; some of them are associated with SLS (Hildebrandt and Zhou, 2007; Hildebrandt et al., 2009). *CEP290* mutations have been described in eight families with SLS, two of which present with intrafamilial clinical variability of neurological and/or renal involvement (Tory et al., 2007). In six families, two mutations segregated, while in two other families, one heterozygous *CEP290* mutation occurred in combination with a homozygous mutation in *NPHP1* and a heterozygous mutation in *NPHP4*, respectively (Helou et al., 2007; Tory et al., 2007). The age at which ESRD occurred ranged from

Deleted: depending on the age of onset of ESRD

Deleted: six

Deleted: , respectively

Deleted: ESRD

Deleted: between

5 to 40 years and retinal degeneration was usually severe (Sayer et al., 2006; Helou et al., 2007; Tory et al., 2007; Coppieters et al., 2010). It is presumed that *CEP290* mutations do not represent a major cause of NPHP/SLS, since large-scale mutation screening in almost 100 families with SLS (Helou et al., 2007; O'Toole et al., 2007) and 21 families with isolated NPHP revealed mutations in only two patients with SLS and a heterozygous unclassified variant in one patient with NPHP (Helou et al., 2007).

Deleted: and

Deleted: 34

Deleted: One exception is patient F848, heterozygous for one *NPHP4* and one *CEP290* mutation, who displayed ESRD at the age of 40 and late-onset progressive RP (Helou et al., 2007).

Deleted: ,

Joubert syndrome (JS) and Joubert syndrome related disorders (JSRD)

Joubert syndrome (JS, MIM[213300]) is a genetically heterogeneous disorder of which the main phenotypic hallmarks are hypotonia, ataxia, psychomotor delay and variable occurrence of oculomotor apraxia and neonatal breathing abnormalities. The most consistent feature, the “molar tooth sign” (MTS), is visible on magnetic resonance imaging (MRI), and consists of a deep interpeduncular fossa with narrow isthmus, thickened, elongated and mal-oriented superior cerebellar peduncles and cerebellar vermis aplasia/hypoplasia (Doherty, 2009). In addition to pure JS, a range of disorders exists that share the MTS and the main neurological signs of JS, yet are distinct due to the involvement of other organs. They are called Joubert syndrome-related disorders (JSRD) and consist of five major subgroups: JS associated with retinopathy, JS associated with renal involvement, cerebello-oculo-renal syndrome (CORS or JS-SLS), COACH syndrome (MIM[216360]) and orofacioidigital syndrome type VI (OFDVI, MIM[277170]) (Valente et al., 2008).

Deleted: AR

Deleted: a unique constellation of midbrain-hindbrain abnormalities, seen

Deleted: .

Deleted: It is called “molar tooth sign” (MTS)

Deleted: essentially

Deleted: from JS

Deleted: .

Deleted: Based on additional features, Valente and coworkers defined the following five subgroups:

Currently, less than 50% of AR cases can be attributed to mutations in nine genes, which all encode ciliary proteins, as far as known (Valente et al., 2008; Bielas et al., 2009; Doherty, 2009; Valente et al., 2010). *CEP290* mutations are a major cause of JSRD, in particular the CORS

Deleted: L

Deleted: seven

Deleted: (nine loci)

subgroup. Approximately 50% of cases with CORS are associated with *CEP290* mutations. In contrast, only a small fraction (~20%) of *CEP290* mutations contributes to the other JSRD subgroups (Valente et al., 2008). So far, only two families with classic JS harbored *CEP290* mutations, one of which displayed intrafamilial variability of the renal phenotype (Valente et al., 2006; Brancati et al., 2007). In most cases, NPHP was of the juvenile type, with development of renal failure toward the end of the first decade or early in the second decade, whereas retinal degeneration mostly consisted of congenital blindness. Interestingly, several patients displayed associated features reminiscent of other subgroups or overlapping ciliopathies, including cleft palate, abnormal liver ultrasound, elevated liver enzymes, Hirschsprung disease, occipital (meningo)encephalocele, atrial/ventricular septal defects, cardiomegaly, postaxial polydactyly, *situs inversus*, lobulated tongue, retinal coloboma, empty sella, hepatic fibrosis, recurrent otitis media and hearing loss (Valente et al., 2006; Brancati et al., 2007; Helou et al., 2007; Tory et al., 2007; Coppieters et al., 2010).

Deleted: patients

Deleted: one

Deleted: However, renal failure at an age of 4 and 25 was also reported (Brancati et al., 2007; Tory et al., 2007). Retinal degeneration mostly consisted of congenital blindness, although RP has also been described in a few patients (Brancati et al., 2007; Helou et al., 2007).

Deleted: . These features include

Meckel-Grüber syndrome (MKS)

Meckel-Grüber syndrome (MKS, MIM[249000]) is a neonatally lethal disorder characterized by a combination of central nervous system malformations (typically occipital [meningo]encephalocele), bilateral cystic kidney dysplasia, ductal proliferation in the portal area of the liver and postaxial polydactyly. Associated features may include cardiac abnormalities, developmental anomalies of external or internal genitalia, cleft palate, *situs inversus* and others. The worldwide incidence ranges from 1/13,250 to 1/140,000 live births (Alexiev et al., 2006). Some cases present with incomplete phenotypes that are called “Meckel-like syndrome” (MIM[208540]) and probably make up a clinical spectrum situated between JSRD and MKS. In addition, a phenotypic and genetic overlap was seen between MKS and BBS (see “Bardet-Biedl

syndrome (BBS)”) (Karmous-Benailly et al., 2005; Leitch et al., 2008). MKS is inherited in an AR fashion with five genes (six loci) identified so far, all encoding centrosomal/ciliary proteins. Mutations in *CEP290* were identified in eight families with MKS and four families with Meckel-like syndrome, further supporting a role for *CEP290* in a wide range of phenotypes (Baala et al., 2007a; Frank et al., 2008).

Bardet-Biedl syndrome (BBS)

Bardet-Biedl syndrome (BBS, MIM[209900]) is a complex multi-organ ciliopathy, characterized by a variable combination of retinal degeneration, obesity, hypogonadism, polydactyly, renal dysfunction and MR. Additional features consist of neurological impairment, speech deficits, craniofacial abnormalities, hearing loss, diabetes mellitus, metabolic defects, cardiovascular abnormalities, hepatic defects and Hirschsprung disease. In most cases, BBS is inherited as an AR trait, with currently 14 genes known. Notably, mutations in different genes have been described in the same patient. These modifiers affect either the expressivity or the overall penetrance of the phenotype (Zaghloul and Katsanis, 2009). In search of a genetic explanation for the partial clinical overlap between BBS and MKS, Leitch and coworkers identified *MKS1* and *CEP290* as disease genes for BBS. Interestingly, the homozygous p.Glu1903X *CEP290* mutation causing BBS was found together with a complex *TMEM67* allele, possibly influencing the phenotype (Leitch et al., 2008).

Deleted: in

Deleted: fashion

Deleted: for which

Deleted: loci

Deleted: are known

Deleted: *MKS3*

Genotype–phenotype correlations

For the majority of mutations, no clear-cut correlation could be established between the genotype and clinical expression. Despite 90 mutations reported exclusively in only one phenotype, 14 others segregated with two diseases while 8 were even associated with three or more phenotypes.

Deleted: 89

1
2 In most cases, these phenotypes are partially overlapping, although few mutations were observed
3
4 to lead to strongly divergent disorders, such as LCA and MKS. Overall, mutations causing
5
6 JS(RD) tend to cluster in the second half of the gene, whereas mutations segregating with LCA,
7
8 SLS and MKS are homogeneously distributed throughout the gene (Brancati et al., 2007; Valente
9
10 et al., 2008) (Supp. Table S1).

Deleted: in

Deleted: M

Deleted: Table 1

11
12 For a few mutations, a genotype-phenotype correlation could be established, albeit to a limited
13
14 extent. The most common mutation in JSRD, p.Gly1890X, was also described in two siblings
15
16 with isolated LCA, in compound heterozygosity with c.2991+1655A>G (Cideciyan et al., 2007).
17
18 Despite the severe retinal phenotype of these siblings and four other patients heterozygous for
19
20 Gly1890X, a milder or even absent visual impairment was seen in eight of nine patients
21
22 homozygous for p.Gly1890X, suggesting that this mutation might be less harmful for retinal
23
24 function (Sayer et al., 2006; Valente et al., 2006; Brancati et al., 2007; Valente et al., 2008).

Deleted: Interestingly, t

25
26 Similarly, a compound heterozygous genotype c.2991+1655G>A/c.451C>T caused an early-
27
28 onset retinal dystrophy phenotype less severe than most CEP290-related LCA, probably due to
29
30 the mild effect of both mutations (Littink et al., 2010). So far, c.2991+1655A>G has only been
31
32 described in patients with isolated LCA. Since a small amount of wild-type product is still
33
34 present, a dosage-dependent mechanism was proposed, in which complete loss of function of
35
36 both alleles would lead to JS, whereas a residual CEP290 activity would be sufficient for normal
37
38 cerebellar and renal function but not for correct retinal activity (den Hollander et al., 2006).
39
40 However, subsequent identification of truncating mutations on both alleles in several LCA
41
42 patients countered the latter hypothesis (Perrault et al., 2007). In addition, we identified
43
44 c.2991+1655A>G in two patients with features suggestive of renal dysfunction, implicating that
45
46 this mutation is possibly not exclusively associated with isolated LCA (Coppieters et al., 2010).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: the

Deleted: mutation

Deleted: for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A similar hypothesis was proposed for certain other *CEP290* splice site mutations. It was presumed that these do not lead to truncated proteins, but rather to (partial) deletion of one of the CCs. In contrast to truncating mutations, these do not seem to hamper normal neurologic development. Examples are two first-degree cousins, each carrying p.Leu1884ThrfsX23 on one allele, but a different *CEP290* mutation on the other. One of them harbored a nonsense mutation and presented with JS without renal involvement by the age of eight, whereas the other was heterozygous for c.4195-1G>A and suffered from SLS without neurologic symptoms (Tory et al., 2007). In addition, a homozygous splice site mutation segregated with SLS in a Turkish family (Sayer et al., 2006). However, in two other unrelated patients with neurological involvement, two distinct splice site mutations were detected. Of note, in both cases, one of both mutations does not affect a consensus splice site (c.1711+5A>G and c.6271-8T>G) (Perrault et al., 2007; Tory et al., 2007).

Deleted: stated

Deleted: Therefore

Deleted: they

Deleted: might allow

Deleted: , in contrast to truncating mutations

Deleted: This is based on clinical findings in

Deleted: one

For all *CEP290*-related phenotypes, different degrees of neurological, ocular and renal involvement were observed between unrelated patients harboring the same *CEP290* genotype. A homozygous p.Lys1575X mutation was detected in four patients with isolated LCA and normal development, one patient with LCA and autistic behavior but normal MRI, one patient with LCA and severe MR (of whom no MRI was available), and one patient with LCA-JS (proven MTS on MRI) (Perrault et al., 2007; Coppieters et al., 2010). Patients homozygous for p.Gly1890X always displayed characteristics typical of JS but associated features ranged from none over JS with NPHP to CORS (Sayer et al., 2006; Valente et al., 2006; Brancati et al., 2007). A homozygous p.Trp7Cys mutation was identified in two patients of Pakistani origin who suffered from retinal degeneration and NPHP. In only one patient, however, several features suggestive for JS were observed (Valente et al., 2006; Coppieters et al., 2010). In addition, compound

Deleted: for

Deleted: for

Deleted: (isolated JS)

1
2 heterozygous p.Leu1884ThrfsX23 and p.Phe1950LeufsX15 mutations were described in two
3
4 French siblings with CORS (Tory et al., 2007), and two French siblings with Meckel-like
5
6 syndrome, aged 18 and 29 weeks of gestation, respectively (Baala et al., 2007a). Moreover,
7
8 intrafamilial variability was reported in several cases. Perrault and colleagues described two LCA
9
10 families in which all affected sibs carried the same mutations, but displayed different
11
12 neurological involvement (Perrault et al., 2007). In addition, kidney US in two brothers with JS
13
14 (deceased at an age of four and seven months), both homozygous for p.Gln1942X, revealed
15
16 cortical cysts in only one patient (Valente et al., 2006). Overall, this wide clinical spectrum is
17
18 difficult to explain by the *CEP290* genotype alone.
19

Deleted: .

Deleted: In the first family, only one of two affected sibs suffered from autism, whereas in the other family, two out of five affected sibs were mentally retarded

20 21 **Epistatic effect of other components of the ciliary proteome**

22
23 It is presumed that the clinical variability of *CEP290*-related disease might be caused by second-
24
25 site modifier alleles. Since *CEP290* forms a complex with several members of the ciliary
26
27 proteome, variants in these genes are likely to affect the interaction with and function of *CEP290*.
28
29 So far, three ciliary genes have been described in which variants co-occur with *CEP290*
30
31 mutations. The first gene is *AHII*, which is associated with JS(RD) and possibly acts in a
32
33 pathway common with *CEP290* (Ferland et al., 2004; Parisi et al., 2006; Kim et al., 2008; Hsiao
34
35 et al., 2009). Tory and colleagues identified a heterozygous p.Arg830Trp missense variant in a
36
37 CORS patient harboring a homozygous p.Leu1884ThrfsX23 *CEP290* mutation. This *AHII*
38
39 variant was not present in an affected sibling with the same *CEP290* genotype. Interestingly, no
40
41 significant difference could be seen in neurological and ocular manifestation between both sibs,
42
43 albeit that the one carrying p.Arg830Trp displayed renal failure earlier than the other (11 versus
44
45 25 years). In addition, a higher frequency of p.Arg830Trp was observed in patients with *NPHP1*
46
47 mutations and neurological symptoms, in comparison with patients with *NPHP1* mutations
48

Deleted: is in

Deleted: pathway as

lacking neurological involvement or with healthy controls, suggesting an influence on the neurological expression of *NPHP1*-related disease. Mutations in *NPHP1* cause NPHP or SLS, with JS-related neurological involvement in up to 12% of cases (Tory et al., 2007). Recently, a modifying effect of p.Arg830Trp has also been established on the development of retinal degeneration in patients suffering from NPHP, independent of primary mutations in *NPHP1*. *AHII* genetically interacts with *NPHP1* in retinal development and was proven necessary for photoreceptor OS development (Louie et al., 2010). In addition to p.Arg830Trp, we identified a different heterozygous missense variant, p.Asn811Lys, in the most severely affected patient out of three with the same *CEP290* genotype and LCA but with different neurological involvement as well as variable age-of-onset of ESRD. Yet another LCA patient with MR carried a third *AHII* missense variant, p.His758Pro, in combination with two mutations in *CEP290* (Coppieters et al., 2010). Of note, all potential modifier alleles identified in *AHII* so far have been missense variants, located in the strongly conserved WD40 repeat, whereas most of the JS-causing mutations are truncating. Obviously, these variants in *AHII* are not sufficient to explain all of the clinical variability, as no *AHII* mutations were demonstrated in two large cohorts of patients with JS(RD) and *CEP290* mutations, (Brancati et al., 2007; Helou et al., 2007). A second gene considered to harbor a potential modifier allele is *TMEM67* (*MKS3*). A homozygous p.Glu1903X *CEP290* mutation was accompanied by a complex p.[Gly218Ala; Ser320Cys] *TMEM67* allele in a patient with BBS. The *TMEM67* allele is likely to influence the *CEP290*-related phenotype, given the genetic interaction between *cep290* and *Tmem67* in zebrafish and the pathogenic potential of the p.Ser320Cys variant and to a lesser extent the p.Gly218Ala variant (Leitch et al., 2008). *NPHP4*, which is associated with both isolated NPHP and SLS (Otto et al., 2002), is the third gene, since a heterozygous p.Thr627Met mutation in *NPHP4* was identified in a patient with SLS who is also heterozygous for p.Arg1978X in *CEP290* (Hoefele et al., 2005; Helou et

Deleted: and

Deleted: Very

Deleted: r

Deleted: Patients with NPHP carrying p.Arg830Trp have a relative risk of 7.5 (95% CI 4.0–11.2) to develop retinal degeneration.

Deleted: A

Deleted: are

Deleted: could be

Deleted: ,

Deleted: suggesting the involvement of other factors

Deleted: The

Deleted: MKS3

Deleted: TMEM67

Deleted: MKS3

Deleted: MKS3

Deleted: mks3

Deleted: makes up

al., 2007). In addition to the heterozygous alleles identified in *AH11*, *TMEM67* and *NPHP4*, both homozygosity at the *PKHD1* locus and a homozygous *CEP290* mutation were identified in a consanguineous family segregating MKS as well as AR polycystic kidney disease. As expected, a homozygous *CEP290* mutation combined with linkage to the *PKHD1* locus in one sibling with MKS caused a more severe kidney and liver phenotype, in comparison with the other siblings that carried either the same *CEP290* or *PKHD1* genotype (Baala et al., 2007a).

Deleted: MKS3

Conversely, mutations in *CEP290* might affect phenotypes caused by mutations in other ciliary genes. A heterozygous p.Asn96MetfsX29 mutation segregated in two siblings who also harbored a homozygous *NPHP1* deletion. In spite of a common genotype and similar retinal degeneration, these siblings differ in both renal and neurological phenotype, suggesting the involvement of additional factors (Tory et al., 2007). In addition, a heterozygous *CEP290* mutation/variant was identified in two probands that might carry a homozygous mutation in another ciliary gene, since they each originate from consanguineous parents (Helou et al., 2007).

Deleted: that

Molecular diagnostic strategies

Given the large number of coding exons (53), sequencing of *CEP290* is laborious, expensive and requires a considerable amount of DNA. Therefore, first-step analysis might comprise screening for the most recurrent mutations, the choice of which depends on the phenotype of the patient. This approach has been applied successfully by several groups (den Hollander et al., 2006; Perrault et al., 2007; Coppieters et al., 2010). Targeted mutation screening can be performed using denaturing high-performance liquid chromatography (dHPLC) or sequencing. For a few mutations, specific detection techniques are available, such as an allele-specific PCR for c.2991+1655A>G (den Hollander et al., 2006). Moreover, 96 *CEP290* mutations are present on a

Deleted: done

Deleted: by

Deleted: ,

Deleted: , or by other means

1 commercially available microarray, which represents standard genetic screening for LCA by
2 testing for 641 mutations in 13 genes (Asper Ophthalmics, v8.0). In the majority of cases
3
4
5 however, screening of the complete coding region remains necessary, either to identify the
6
7 second disease allele, or to screen for both mutations in case of negative first-pass screening.
8
9 PCR primers and conditions for both sequencing (Sayer et al., 2006; Valente et al., 2006) and
10
11 dHPLC (Brancati et al., 2007) have been published and an alternative pre-screening assay based
12
13 on heteroduplex formation and subsequent CEL I endonuclease digest has been described (Helou
14
15 et al., 2007). Brancati and colleagues first screened parental DNA using dHPLC, followed by
16
17 sequencing of the identified mutations in the affected offspring and of the whole coding region in
18
19 case of a heterozygous mutation (Brancati et al., 2007). Apart from detecting small variants,
20
21 comprehensive *CEP290* screening should also include dosage analysis of all exons, using for
22
23 instance quantitative real-time PCR (Travaglini et al., 2009).
24
25

Deleted: LCA

Deleted: early-onset RP and LCA

Deleted: purposes

Deleted: In order to preserve DNA of affected children.

26 Future Prospects

27
28
29
30 Given the emerging importance of modifier alleles on the phenotypic expression of ciliopathies,
31
32 future studies are required to understand their mechanism of action and to further elucidate the
33
34 ciliary protein networks. The identification of modifiers for retinal, renal, neurological or other
35
36 phenotypes might contribute to an improved predictive power of a *CEP290*-related genotype.
37
38 Early management of patients with a higher risk of NPHP, for instance, may delay the
39
40 progression toward renal failure and minimize secondary complications. In a diagnostic setting,
41
42 mutations in ciliopathies should ideally be evaluated in the context of the entire spectrum of
43
44 ciliary variants. Novel technologies such as next-generation sequencing will play a crucial role in
45
46 this respect. Finally, more insights in the molecular pathogenesis of ciliopathies will eventually
47
48 direct towards therapeutic options, such as gene therapy. Since all *CEP290*-related phenotypes
49

Deleted: necessary

Deleted: clinical

are inherited in an AR manner and the majority of mutations consist of loss-of-function alleles, gene-replacement therapy might indeed be an option.

References

- Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J. 2001. Gene therapy restores vision in a canine model of childhood blindness. *Nat Genet* 28(1):92-5.
- Alexiev BA, Lin X, Sun CC, Brenner DS. 2006. Meckel-Gruber syndrome: pathologic manifestations, minimal diagnostic criteria, and differential diagnosis. *Arch Pathol Lab Med* 130(8):1236-8.
- Ameri K, Harris AL. 2008. Activating transcription factor 4. *Int J Biochem Cell Biol* 40(1):14-21.
- Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M. 2003. Proteomic characterization of the human centrosome by protein correlation profiling. *Nature* 426(6966):570-4.
- Baala L, Audollent S, Martinovic J, Ozilou C, Babron MC, Sivanandamoorthy S, Saunier S, Salomon R, Gonzales M, Rattenberry E, Esculpavit C, Toutain A, Moraine C, Parent P, Marcorelles P, Dauge MC, Roume J, Le Merrer M, Meiner V, Meir K, Menez F, Beaufrere AM, Francannet C, Tantau J, Sinico M, Dumez Y, MacDonald F, Munnich A, Lyonnet S, Gubler MC, Genin E, Johnson CA, Vekemans M, Encha-Razavi F, Attie-Bitach T. 2007a. Pleiotropic effects of CEP290 (NPHP6) mutations extend to Meckel syndrome. *Am J Hum Genet* 81(1):170-9.
- Baala L, Romano S, Khaddour R, Saunier S, Smith UM, Audollent S, Ozilou C, Faivre L, Laurent N, Foliguet B, Munnich A, Lyonnet S, Salomon R, Encha-Razavi F, Gubler MC, Boddaert N, de Lonlay P, Johnson CA, Vekemans M, Antignac C, Attie-Bitach T. 2007b. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. *Am J Hum Genet* 80(1):186-94.
- Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med* 358(21):2231-9.
- Berbari NF, O'Connor AK, Haycraft CJ, Yoder BK. 2009. The primary cilium as a complex signaling center. *Curr Biol* 19(13):R526-35.
- Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS, Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L, Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG. 2009. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. *Nat Genet* 41(9):1032-6.
- Brancati F, Barrano G, Silhavy JL, Marsh SE, Travaglini L, Bielas SL, Amorini M, Zablocka D, Kayserili H, Al-Gazali L, Bertini E, Boltshauser E, D'Hooghe M, Fazzi E, Fenerci EY, Hennekam RC, Kiss A, Lees MM, Marco E, Phadke SR, Rigoli L, Romano S, Salpietro CD, Sherr EH, Signorini S, Stromme P, Stuart B, Sztriha L, Viskochil DH, Yuksel A,

- 1
2 Dallapiccola B, Valente EM, Gleeson JG. 2007. CEP290 mutations are frequently
3 identified in the oculo-renal form of Joubert syndrome-related disorders. *Am J Hum*
4 *Genet* 81(1):104-13.
- 5 Brancati F, Iannicelli M, Travaglini L, Mazzotta A, Bertini E, Boltshauser E, D'Arrigo S, Emma
6 F, Fazzi E, Gallizzi R, Gentile M, Loncarevic D, Mejaski-Bosnjak V, Pantaleoni C, Rigoli
7 L, Salpietro CD, Signorini S, Stringini GR, Verloes A, Zablocka D, Dallapiccola B,
8 Gleeson JG, Valente EM. 2009. MKS3/TMEM67 mutations are a major cause of COACH
9 Syndrome, a Joubert Syndrome related disorder with liver involvement. *Hum Mutat*
10 30(2):E432-42.
- 11 Chang B, Khanna H, Hawes N, Jimeno D, He S, Lillo C, Parapuram SK, Cheng H, Scott A, Hurd
12 RE, Sayer JA, Otto EA, Attanasio M, O'Toole JF, Jin G, Shou C, Hildebrandt F, Williams
13 DS, Heckenlively JR, Swaroop A. 2006. In-frame deletion in a novel centrosomal/ciliary
14 protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset
15 retinal degeneration in the rd16 mouse. *Hum Mol Genet* 15(11):1847-57.
- 16 Chen D, Shou C. 2001. Molecular cloning of a tumor-associated antigen recognized by
17 monoclonal antibody 3H11. *Biochem Biophys Res Commun* 280(1):99-103.
- 18 Cideciyan AV, Aleman TS, Jacobson SG, Khanna H, Sumaroka A, Aguirre GK, Schwartz SB,
19 Windsor EA, He S, Chang B, Stone EM, Swaroop A. 2007. Centrosomal-ciliary gene
20 CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors
21 and visual brain: implications for therapy of Leber congenital amaurosis. *Hum Mutat*
22 28(11):1074-83.
- 23 Coppiaeters F, Casteels I, Meire FM, De Jaegere S, Hooghe S, Van Regemorter N, Van Esch H,
24 Matulevičienė A, Castedo S, Meersschant V, Walraedt S, Standaert L, Coucke P, Hoeben
25 H, Kroes HY, Vande Walle J, de Ravel T, Leroy BP, De Baere E. 2010. Genetic
26 screening of LCA in Belgium: predominance of CEP290 and identification of potential
27 modifier alleles in AHI1 of CEP290-related phenotypes. [Under review.](#)
- 28 den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, Zonneveld MN,
29 Strom TM, Meitinger T, Brunner HG, Hoyng CB, van den Born LI, Rohrschneider K,
30 Cremers FP. 2006. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber
31 congenital amaurosis. *Am J Hum Genet* 79(3):556-61.
- 32 den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. 2008. Leber congenital amaurosis:
33 genes, proteins and disease mechanisms. *Prog Retin Eye Res* 27(4):391-419.
- 34 Doherty D. 2009. Joubert syndrome: insights into brain development, cilium biology, and
35 complex disease. *Semin Pediatr Neurol* 16(3):143-54.
- 36 Doherty D, Parisi MA, Finn LS, Gunay-Aygun M, Al-Mateen M, Bates D, Clericuzio C, Demir
37 H, Dorschner M, van Essen AJ, Gahl WA, Gentile M, Gorden NT, Hikida A, Knutzen D,
38 Ozyurek H, Phelps I, Rosenthal P, Verloes A, Weigand H, Chance PF, Dobyns WB, Glass
39 IA. 2009. Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH
40 syndrome (Joubert syndrome with congenital hepatic fibrosis). *J Med Genet* 47(1):8-21.
- 41 [Dryja TP, Adams SM, Grimsby JL, McGee TL, Hong DH, Li T, Andreasson S, Berson EL. 2001.](#)
42 [Null RPGRIP1 alleles in patients with Leber congenital amaurosis. *Am J Hum Genet*](#)
43 [68\(5\):1295-8.](#)
- 44 Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill RS, Al-Nouri D, Al-Rumayyan A, Topcu M,
45 Gascon G, Bodell A, Shugart YY, Ruvolo M, Walsh CA. 2004. Abnormal cerebellar
46 development and axonal decussation due to mutations in AHI1 in Joubert syndrome. *Nat*
47 *Genet* 36(9):1008-13.

Deleted: Submitted

Deleted: .

- 1
2 Frank V, den Hollander AI, Bruchle NO, Zonneveld MN, Nurnberg G, Becker C, Du Bois G,
3 Kendziorra H, Roosing S, Senderek J, Nurnberg P, Cremers FP, Zerres K, Bergmann C.
4 2008. Mutations of the CEP290 gene encoding a centrosomal protein cause Meckel-
5 Gruber syndrome. *Hum Mutat* 29(1):45-52.
- 6 Gerdes JM, Davis EE, Katsanis N. 2009. The vertebrate primary cilium in development,
7 homeostasis, and disease. *Cell* 137(1):32-45.
- 8 Gorden NT, Arts HH, Parisi MA, Coene KL, Letteboer SJ, van Beersum SE, Mans DA, Hikida
9 A, Eckert M, Knutzen D, Alswaid AF, Ozyurek H, Dibooglu S, Otto EA, Liu Y, Davis
10 EE, Hutter CM, Bammler TK, Farin FM, Dorschner M, Topcu M, Zackai EH, Rosenthal
11 P, Owens KN, Katsanis N, Vincent JB, Hildebrandt F, Rubel EW, Raible DW, Knoers
12 NV, Chance PF, Roepman R, Moens CB, Glass IA, Doherty D. 2008. CC2D2A is
13 mutated in Joubert syndrome and interacts with the ciliopathy-associated basal body
14 protein CEP290. *Am J Hum Genet* 83(5):559-71.
- 15 Grantham R. 1974. Amino acid difference formula to help explain protein evolution. *Science*
16 185(4154):862-4.
- 17 Guo J, Jin G, Meng L, Ma H, Nie D, Wu J, Yuan L, Shou C. 2004. Subcellular localization of
18 tumor-associated antigen 3H11Ag. *Biochem Biophys Res Commun* 324(2):922-30.
- 19 Hanein S, Perrault I, Gerber S, Tanguy G, Barbet F, Ducroq D, Calvas P, Dollfus H, Hamel C,
20 Lopponen T, Munier F, Santos L, Shalev S, Zafeiriou D, Dufier JL, Munnich A, Rozet
21 JM, Kaplan J. 2004. Leber congenital amaurosis: comprehensive survey of the genetic
22 heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations
23 as a strategy for molecular diagnosis. *Hum Mutat* 23(4):306-17.
- 24 Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye
25 SL, Flotte TR, Byrne BJ, Jacobson SG. 2008. Treatment of leber congenital amaurosis
26 due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene
27 vector: short-term results of a phase I trial. *Hum Gene Ther* 19(10):979-90.
- 28 Helou J, Otto EA, Attanasio M, Allen SJ, Parisi MA, Glass I, Utsch B, Hashmi S, Fazzi E,
29 Omran H, O'Toole JF, Sayer JA, Hildebrandt F. 2007. Mutation analysis of
30 NPHP6/CEP290 in patients with Joubert syndrome and Senior-Loken syndrome. *J Med*
31 *Genet* 44(10):657-63.
- 32 Hildebrandt F, Attanasio M, Otto E. 2009. Nephronophthisis: disease mechanisms of a ciliopathy.
33 *J Am Soc Nephrol* 20(1):23-35.
- 34 Hildebrandt F, Zhou W. 2007. Nephronophthisis-associated ciliopathies. *J Am Soc Nephrol*
35 18(6):1855-71.
- 36 Hoefele J, Sudbrak R, Reinhardt R, Lehrack S, Hennig S, Imm A, Muerb U, Utsch B, Attanasio
37 M, O'Toole JF, Otto E, Hildebrandt F. 2005. Mutational analysis of the NPHP4 gene in
38 250 patients with nephronophthisis. *Hum Mutat* 25(4):411.
- 39 Hong DH, Pawlyk B, Sokolov M, Strissel KJ, Yang J, Tulloch B, Wright AF, Arshavsky VY, Li
40 T. 2003. RPGR isoforms in photoreceptor connecting cilia and the transitional zone of
41 motile cilia. *Invest Ophthalmol Vis Sci* 44(6):2413-21.
- 42 Hsiao YC, Tong ZJ, Westfall JE, Ault JG, Page-McCaw PS, Ferland RJ. 2009. Ahi1, whose
43 human ortholog is mutated in Joubert syndrome, is required for Rab8a localization,
44 ciliogenesis and vesicle trafficking. *Hum Mol Genet* 18(20):3926-41.
- 45 Karmous-Benailly H, Martinovic J, Gubler MC, Sirot Y, Clech L, Ozilou C, Auge J, Brahimi N,
46 Etchevers H, Detrait E, Esculpavit C, Audollent S, Goudefroye G, Gonzales M, Tantau J,
47 Loget P, Joubert M, Gaillard D, Jeanne-Pasquier C, Delezoide AL, Peter MO, Plessis G,
48 Simon-Bouy B, Dollfus H, Le Merrer M, Munnich A, Encha-Razavi F, Vekemans M,

- 1
2 Attie-Bitach T. 2005. Antenatal presentation of Bardet-Biedl syndrome may mimic
3 Meckel syndrome. *Am J Hum Genet* 76(3):493-504.
- 4 Kim J, Krishnaswami SR, Gleeson JG. 2008. CEP290 interacts with the centriolar satellite
5 component PCM-1 and is required for Rab8 localization to the primary cilium. *Hum Mol*
6 *Genet* 17(23):3796-805.
- 7 Leitch CC, Zaghoul NA, Davis EE, Stoetzel C, Diaz-Font A, Rix S, Al-Fadhel M, Lewis RA,
8 Eyaïd W, Banin E, Dollfus H, Beales PL, Badano JL, Katsanis N. 2008. Hypomorphic
9 mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome.
10 *Nat Genet* 40(4):443-8.
- 11 Li Y, Wang H, Peng J, Gibbs RA, Lewis RA, Lupski JR, Mardon G, Chen R. 2009. Mutation
12 survey of known LCA genes and loci in the Saudi Arabian population. *Invest Ophthalmol*
13 *Vis Sci* 50(3):1336-43.
- 14 Littink KW, Pott JW, Collin RW, Kroes HY, Verheij JB, Blokland EA, de Castro Miro M,
15 Hoyng CB, Klaver C, Koenekoop RK, Rohrschneider K, Cremers FP, van den Born I, den
16 Hollander AI. 2010. A novel nonsense mutation in CEP290 induces exon skipping and
17 leads to a relatively mild retinal phenotype. *Invest Ophthalmol Vis Sci*. [In Press](#).
- 18 Louie CM, Caridi G, Lopes VS, Brancati F, Kispert A, Lancaster MA, Schlossman AM, Otto EA,
19 Leitges M, Grone HJ, Lopez I, Gudiseva HV, O'Toole JF, Vallespin E, Ayyagari R,
20 Ayuso C, Cremers FP, den Hollander AI, Koenekoop RK, Dallapiccola B, Ghiggeri GM,
21 Hildebrandt F, Valente EM, Williams DS, Gleeson JG. 2010. AHI1 is required for
22 photoreceptor outer segment development and is a modifier for retinal degeneration in
23 nephronophthisis. *Nat Genet* [42\(2\):175-80](#).
- 24 Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL,
25 Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B,
26 Zeleniaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace
27 EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP,
28 Simonelli F, Gauderman JB. 2009. Age-dependent effects of RPE65 gene therapy for
29 Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet* [375\(9708\):30](#).
- 30 Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall
31 KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J,
32 Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zeleniaia O,
33 Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA,
34 Bennett J. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N*
35 *Engl J Med* 358(21):2240-8.
- 36 McEwen DP, Koenekoop RK, Khanna H, Jenkins PM, Lopez I, Swaroop A, Martens JR. 2007.
37 Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of
38 G proteins in cilia of olfactory sensory neurons. *Proc Natl Acad Sci U S A*
39 104(40):15917-22.
- 40 [Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A, Carvalho MR, Achatz H,](#)
41 [Hellebrand H, Lennon A, Migliaccio C, Porter K, Zrenner E, Bird A, Jay M, Lorenz B,](#)
42 [Wittwer B, D'Urso M, Meitinger T, Wright A. 1996. A gene \(RPGR\) with homology to](#)
43 [the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa](#)
44 [\(RP3\). *Nat Genet* 13\(1\):35-42.](#)
- 45 Menotti-Raymond M, David VA, Schaffer AA, Stephens R, Wells D, Kumar-Singh R, O'Brien
46 SJ, Narfstrom K. 2007. Mutation in CEP290 discovered for cat model of human retinal
47 degeneration. *J Hered* 98(3):211-20.

Deleted: .

Deleted: .

- 1
2 Nagase T, Ishikawa K, Nakajima D, Ohira M, Seki N, Miyajima N, Tanaka A, Kotani H, Nomura
3 N, Ohara O. 1997. Prediction of the coding sequences of unidentified human genes. VII.
4 The complete sequences of 100 new cDNA clones from brain which can code for large
5 proteins in vitro. *DNA Res* 4(2):141-50.
- 6 Nagy E, Maquat LE. 1998. A rule for termination-codon position within intron-containing genes:
7 when nonsense affects RNA abundance. *Trends Biochem Sci* 23(6):198-9.
- 8 Narfstrom K, David V, Jarret O, Beatty J, Barrs V, Wilkie D, O'Brien S, Menotti-Raymond M.
9 2009. Retinal degeneration in the Abyssinian and Somali cat (rdAc): correlation between
10 genotype and phenotype and rdAc allele frequency in two continents. *Vet Ophthalmol*
11 12(5):285-91.
- 12 Nigg EA, Raff JW. 2009. Centrioles, centrosomes, and cilia in health and disease. *Cell*
13 139(4):663-78.
- 14 O'Toole JF, Otto EA, Hoefele J, Helou J, Hildebrandt F. 2007. Mutational analysis in 119
15 families with nephronophthisis. *Pediatr Nephrol* 22(3):366-70.
- 16 Otto E, Hoefele J, Ruf R, Mueller AM, Hiller KS, Wolf MT, Schuermann MJ, Becker A,
17 Birkenhager R, Sudbrak R, Hennies HC, Nurnberg P, Hildebrandt F. 2002. A gene
18 mutated in nephronophthisis and retinitis pigmentosa encodes a novel protein,
19 nephroretinin, conserved in evolution. *Am J Hum Genet* 71(5):1161-7.
- 20 Otto EA, Loeys B, Khanna H, Hellemans J, Sudbrak R, Fan S, Muerb U, O'Toole JF, Helou J,
21 Attanasio M, Utsch B, Sayer JA, Lillo C, Jimeno D, Coucke P, De Paepe A, Reinhardt R,
22 Klages S, Tsuda M, Kawakami I, Kusakabe T, Omran H, Imm A, Tippens M, Raymond
23 PA, Hill J, Beales P, He S, Kispert A, Margolis B, Williams DS, Swaroop A, Hildebrandt
24 F. 2005. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken
25 syndrome and interacts with RPGR and calmodulin. *Nat Genet* 37(3):282-8.
- 26 Parisi MA, Doherty D, Eckert ML, Shaw DW, Ozyurek H, Aysun S, Giray O, Al Swaid A, Al
27 Shahwan S, Dohayan N, Bakhsh E, Indridason OS, Dobyns WB, Bennett CL, Chance PF,
28 Glass IA. 2006. AHI1 mutations cause both retinal dystrophy and renal cystic disease in
29 Joubert syndrome. *J Med Genet* 43(4):334-9.
- 30 Pasadhika S, Fishman GA, Stone EM, Lindeman M, Zelkha R, Lopez I, Koenekoop RK, Shahidi
31 M. 2009. Differential Macular Morphology in Patients with RPE65, CEP290, GUCY2D
32 and AIPL1 Related Leber Congenital Amaurosis. *Invest Ophthalmol Vis Sci* [51\(5\):2608-
33 14](#).
- 34 Perrault I, Delphin N, Hanein S, Gerber S, Dufier JL, Roche O, Defoort-Dhellemmes S, Dollfus
35 H, Fazzi E, Munnich A, Kaplan J, Rozet JM. 2007. Spectrum of NPHP6/CEP290
36 mutations in Leber congenital amaurosis and delineation of the associated phenotype.
37 *Hum Mutat* 28(4):416.
- 38 Salomon R, Saunier S, Niaudet P. 2009. Nephronophthisis. *Pediatr Nephrol* 24(12):2333-44.
- 39 Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J,
40 Attanasio M, Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I,
41 Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou
42 C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA, Petry
43 M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A,
44 Leroux MR, Hildebrandt F. 2006. The centrosomal protein nephrocystin-6 is mutated in
45 Joubert syndrome and activates transcription factor ATF4. *Nat Genet* 38(6):674-81.
- 46 Schafer T, Putz M, Lienkamp S, Ganner A, Bergbreiter A, Ramachandran H, Gieloff V, Gerner
47 M, Mattonet C, Czarniecki PG, Sayer JA, Otto EA, Hildebrandt F, Kramer-Zucker A,
48
49
50
51
52
53
54
55
56
57
58
59
60

Deleted: .

- 1
2 Walz G. 2008. Genetic and physical interaction between the NPHP5 and NPHP6 gene
3 products. *Hum Mol Genet* 17(23):3655-62.
- 4 Seong MW, Kim SY, Yu YS, Hwang JM, Kim JY, Park SS. 2008. Molecular characterization of
5 Leber congenital amaurosis in Koreans. *Mol Vis* 14:1429-36.
- 6 Shu X, Black GC, Rice JM, Hart-Holden N, Jones A, O'Grady A, Ramsden S, Wright AF. 2007.
7 RPGR mutation analysis and disease: an update. *Hum Mutat* 28(4):322-8.
- 8 Simms RJ, Eley L, Sayer JA. 2009. Nephronophthisis. *Eur J Hum Genet* 17(4):406-16.
- 9 Simonelli F, Ziviello C, Testa F, Rossi S, Fazzi E, Bianchi PE, Fossarello M, Signorini S,
10 Bertone C, Galantuomo S, Brancati F, Valente EM, Ciccodicola A, Rinaldi E, Auricchio
11 A, Banfi S. 2007. Clinical and molecular genetics of Leber's congenital amaurosis: a
12 multicenter study of Italian patients. *Invest Ophthalmol Vis Sci* 48(9):4284-90.
- 13 Smith UM, Consugar M, Tee LJ, McKee BM, Maina EN, Whelan S, Morgan NV, Goranson E,
14 Gissen P, Lilliquist S, Aligianis IA, Ward CJ, Pasha S, Punyashthiti R, Malik Sharif S,
15 Batman PA, Bennett CP, Woods CG, McKeown C, Bucourt M, Miller CA, Cox P,
16 Algazali L, Trembath RC, Torres VE, Attie-Bitach T, Kelly DA, Maher ER, Gattone VH,
17 2nd, Harris PC, Johnson CA. 2006. The transmembrane protein meckelin (MKS3) is
18 mutated in Meckel-Gruber syndrome and the wpk rat. *Nat Genet* 38(2):191-6.
- 19 Stone EM. 2003. Finding and interpreting genetic variations that are important to
20 ophthalmologists. *Trans Am Ophthalmol Soc* 101:437-84.
- 21 Sundaresan P, Vijayalakshmi P, Thompson S, Ko AC, Fingert JH, Stone EM. 2009. Mutations
22 that are a common cause of Leber congenital amaurosis in northern America are rare in
23 Southern India. *Mol Vis* 15:1781-7.
- 24 Tallila J, Jakkula E, Peltonen L, Salonen R, Kestila M. 2008. Identification of CC2D2A as a
25 Meckel syndrome gene adds an important piece to the ciliopathy puzzle. *Am J Hum*
26 *Genet* 82(6):1361-7.
- 27 Tammachote R, Hommerding CJ, Sindors RM, Miller CA, Czarnecki PG, Leightner AC,
28 Salisbury JL, Ward CJ, Torres VE, Gattone VH, 2nd, Harris PC. 2009. Ciliary and
29 centrosomal defects associated with mutation and depletion of the Meckel syndrome
30 genes MKS1 and MKS3. *Hum Mol Genet* 18(17):3311-23.
- 31 | Thompson S, Whiting RE, Kardon RH, Stone EM, Narfstrom K. 2010. Effects of hereditary
32 retinal degeneration due to a CEP290 mutation on the feline pupillary light reflex. *Vet*
33 *Ophthalmol* 13(3):151-7.
- 34 | Torrado M, Iglesias R, Nespereira B, Mikhailov AT. 2010. Identification of candidate genes
35 potentially relevant to chamber-specific remodeling in postnatal ventricular myocardium.
36 *J Biomed Biotechnol* 2010:603159.
- 37 Tory K, Lacoste T, Burglen L, Moriniere V, Boddaert N, Macher MA, Llanas B, Nivet H,
38 Bensman A, Niaudet P, Antignac C, Salomon R, Saunier S. 2007. High NPHP1 and
39 NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential
40 epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. *J Am*
41 *Soc Nephrol* 18(5):1566-75.
- 42 Travaglini L, Brancati F, Attie-Bitach T, Audollent S, Bertini E, Kaplan J, Perrault I, Iannicelli
43 M, Mancuso B, Rigoli L, Rozet JM, Swistun D, Tolentino J, Dallapiccola B, Gleeson JG,
44 Valente EM, Zankl A, Leventer R, Grattan-Smith P, Janecke A, D'Hooghe M, Sznajer Y,
45 Van Coster R, Demerleir L, Dias K, Moco C, Moreira A, Kim CA, Maegawa G, Petkovic
46 D, Abdel-Salam GM, Abdel-Aleem A, Zaki MS, Marti I, Quijano-Roy S, Sigaudy S, de
47 Lonlay P, Romano S, Touraine R, Koenig M, Lagier-Tourenne C, Messer J, Collignon P,
48 Wolf N, Philippini H, Kitsiou Tzeli S, Halldorsson S, Johannsdottir J, Ludvigsson P,

- 1
2 Phadke SR, Udani V, Stuart B, Magee A, Lev D, Michelson M, Ben-Zeev B, Fischetto R,
3 Benedicenti F, Stanzial F, Borgatti R, Accorsi P, Battaglia S, Fazzi E, Giordano L, Pinelli
4 L, Boccone L, Bigoni S, Ferlini A, Donati MA, Caridi G, Divizia MT, Faravelli F,
5 Ghiggeri G, Pessagno A, Briguglio M, Briuglia S, Salpietro CD, Tortorella G, Adami A,
6 Castorina P, Lalatta F, Marra G, Riva D, Scelsa B, Spaccini L, Uziel G, Del Giudice E,
7 Laverda AM, Ludwig K, Permunionian A, Suppiej A, Signorini S, Uggetti C, Battini R, Di
8 Giacomo M, Cilio MR, Di Sabato ML, Leuzzi V, Parisi P, Pollazzon M, Silengo M, De
9 Vescovi R, Greco D, Romano C, Cazzagon M, Simonati A, Al-Tawari AA, Bastaki L,
10 Megarbane A, Sabolic Avramovska V, de Jong MM, Stromme P, Koul R, Rajab A, Azam
11 M, Barbot C, Martorell Sampol L, Rodriguez B, Pascual-Castroviejo I, Teber S, Anlar B,
12 Comu S, Karaca E, Kayserili H, Yuksel A, Akcakus M, Al Gazali L, Sztriha L, Nicholl D,
13 Woods CG, Bennett C, Hurst J, Sheridan E, Barnicoat A, Hennekam R, Lees M, Blair E,
14 Bernes S, Sanchez H, Clark AE, DeMarco E, Donahue C, Sherr E, Hahn J, Sanger TD,
15 Gallager TE, Dobyns WB, Daugherty C, Krishnamoorthy KS, Sarco D, Walsh CA,
16 McKanna T, Milisa J, Chung WK, De Vivo DC, Raynes H, Schubert R, Seward A,
17 Brooks DG, Goldstein A, Caldwell J, Finsecke E, Maria BL, Holden K, Cruse RP,
18 Swoboda KJ, Viskochil D. 2009. Expanding CEP290 mutational spectrum in ciliopathies.
19 *Am J Med Genet A* 149A(10):2173-80.
- 20 Tsang WY, Bossard C, Khanna H, Peranen J, Swaroop A, Malhotra V, Dynlacht BD. 2008.
21 CP110 suppresses primary cilia formation through its interaction with CEP290, a protein
22 deficient in human ciliary disease. *Dev Cell* 15(2):187-97.
- 23 Valente EM, Brancati F, Dallapiccola B. 2008. Genotypes and phenotypes of Joubert syndrome
24 and related disorders. *Eur J Med Genet* 51(1):1-23.
- 25 Valente EM, Logan CV, Mougou-Zerelli S, Lee JH, Silhavy JL, Brancati F, Iannicelli M,
26 Travaglini L, Romani S, Illi B, Adams M, Szymanska K, Mazzotta A, Lee JE, Tolentino
27 JC, Swistun D, Salpietro CD, Fede C, Gabriel S, Russ C, Cibulskis K, Sougnez C,
28 Hildebrandt F, Otto EA, Held S, Diplas BH, Davis EE, Mikula M, Strom CM, Ben-Zeev
29 B, Lev D, Sagie TL, Michelson M, Yaron Y, Krause A, Boltshauser E, Elkhartoufi N,
30 Roume J, Shalev S, Munnich A, Saunier S, Inglehearn C, Saad A, Alkindy A, Thomas S,
31 Vekemans M, Dallapiccola B, Katsanis N, Johnson CA, Attie-Bitach T, Gleeson JG.
32 2010. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related
33 syndromes. *Nat Genet.* [In Press.](#)
- 34 Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, Lancaster MA,
35 Boltshauser E, Boccone L, Al-Gazali L, Fazzi E, Signorini S, Louie CM, Bellacchio E,
36 Bertini E, Dallapiccola B, Gleeson JG. 2006. Mutations in CEP290, which encodes a
37 centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat Genet* 38(6):623-5.
- 38 Vallespin E, Lopez-Martinez MA, Cantalapiedra D, Riveiro-Alvarez R, Aguirre-Lamban J,
39 Avila-Fernandez A, Villaverde C, Trujillo-Tiebas MJ, Ayuso C. 2007. Frequency of
40 CEP290 c.2991_1655A>G mutation in 175 Spanish families affected with Leber
41 congenital amaurosis and early-onset retinitis pigmentosa. *Mol Vis* 13:2160-2.
- 42 Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, Traboulsi EI, Weleber RG,
43 Pennesi ME, Heon E, Drack A, Lam BL, Allikmets R, Stone EM. 2010. Visual Acuity in
44 Patients with Leber's Congenital Amaurosis and Early Childhood-Onset Retinitis
45 Pigmentosa. *Ophthalmology* [117:1190-1198.](#)
- 46 Wang M, Bridges JP, Na CL, Xu Y, Weaver TE. 2009. Meckel-Gruber syndrome protein MKS3
47 is required for endoplasmic reticulum-associated degradation of surfactant protein C. *J*
48 *Biol Chem* 284(48):33377-83.

Deleted: .

1
2 Zaghoul NA, Katsanis N. 2009. Mechanistic insights into Bardet-Biedl syndrome, a model
3 ciliopathy. J Clin Invest 119(3):428-37.
4

5
6
7 Figure legends

Deleted: ¶

8
9
10 **Figure 1: Overview of all mutations and variants currently present in *CEP290*base.**

11 The exact location of the mutation/variant is depicted with respect to the *CEP290* protein (Sayer
12 et al., 2006). If no protein effect is known, the c.DNA nomenclature is used. Mutations
13 depicted twice have been reported to arise from different nucleotide changes.
14
15

16
17
18 **Figure 2: Overlap of *CEP290* mutations between different diseases.**

19 Abbreviations used: LCA: Leber Congenital Amaurosis; SLS: Senior-Loken syndrome; JS:
20 Joubert syndrome; JS + RD: Joubert syndrome with associated retinopathy; JS + RF:
21 Joubert syndrome with associated renal failure; CORS: cerebello-oculo-renal syndrome;
22 MKS: Meckel-Grüber syndrome; MKS-like: Meckel-Grüber syndrome – like; BBS:
23 Bardet-Biedl syndrome.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Overview of all mutations and variants currently present in CEP290base.
 The exact location of the mutation/variant is depicted with respect to the CEP290 protein (Sayer et al., 2006). If no protein effect is known, the c.DNA nomenclature is used. Mutations depicted twice have been reported to arise from different nucleotide changes.
 291x141mm (300 x 300 DPI)




Figure 1: Overview of all mutations and variants currently present in CEP290base.
 The exact location of the mutation/variant is depicted with respect to the CEP290 protein (Sayer et al., 2006). If no protein effect is known, the c.DNA nomenclature is used. Mutations depicted twice have been reported to arise from different nucleotide changes.
 291x141mm (300 x 300 DPI)





Figure 2: Overlap of CEP290 mutations between different diseases.

Abbreviations used: LCA: Leber Congenital Amaurosis; SLS: Senior-Loken syndrome; JS: Joubert syndrome; JS + RD: Joubert syndrome with associated retinopathy; JS + RF: Joubert syndrome with associated renal failure; CORS: cerebello-oculo-renal syndrome; MKS: Meckel-Grüber syndrome; MKS-like: Meckel-Grüber syndrome – like; BBS: Bardet-Biedl syndrome.

165x121mm (300 x 300 DPI)



Deleted: 3

Table 1: Overview of selected ciliary proteins interacting with CEP290, and their involvement in partially overlapping yet distinct ciliopathies.

Protein	Associated phenotype						
	RD	NPHP	SLS	JS(RD)	MKS	BBS	COACH
CEP290	(den Hollander et al., 2006)	(Helou et al., 2007)(?)	(Sayer et al., 2006)	(Sayer, et al., 2006; Valente et al., 2006)	(Baala et al., 2007a)	(Leitch et al., 2008)	
CEP290 interacting proteins	RPGR	(Meindl et al., 1996)					
	RPGRI1	(Dryja et al., 2001)					
	NPHP5		(Otto et al., 2005)				
	TMEM67 (MKS3)				(Baala et al., 2007b)	(Smith et al., 2006)	(Brancati et al., 2009)
	CC2D2A				(Gorden et al., 2008)	(Tallila et al., 2008)	(Doherty et al., 2009)

Deleted: MKS3¶

Deleted: TMEM67

Abbreviations used: RD: retinal degeneration; NPHP: nephronophthisis; SLS: Senior-Loken

syndrome; JS(RD): Joubert syndrome (related disorders); MKS: Meckel-Grüber syndrome; BBS:

Bardet-Biedl syndrome; COACH: cerebellar vermis hypo/aplasia, oligophrenia, congenital

ataxia, ocular coloboma, and hepatic fibrosis; (?): uncertain association.


Supp. Figure S1: Overview of CEP290base

1 Mutation Overview

Variant ID	Variant type	Exon/Intron	Nucleotide changed	Base change type	Protein changed	Protein change type	Number of amino acids	dbSNP ID	OMIM ID	RefSeq Prot ID
34	mutation	Exon 2	C275A	base substitution	p.Met17	unknown	1			
41	mutation	Exon 7	C755T	base substitution	p.Met17	unknown	1			
5	mutation	Exon 2	C216A>T	base substitution	p.Trp7Cys	missense (amino acid sub)	2	rs2033298	610442.0003	NR_128294
53	mutation	Intron 2	C-103_103-18del	base(s) deletion	p.?	unknown	1			
93	mutation	Exon 3	C-154_157del	base(s) deletion	p.Trp55Asn63	truncating deletion	1			
12	mutation	Intron 2	C189+10T	base substitution	p.?	unknown	1		610442.0009	
18	mutation	Exon 2	C382A>T	base substitution	p.?	unknown	1			
21	mutation	Exon 5	C263dup	duplication	p.Trp166Met167	truncating deletion	1			
78	mutation	Exon 5	C287del	base(s) deletion	p.Asn166Met165	truncating deletion	1			
122	polymorphism	Intron 3	C-227-10del+G	base substitution	p.?	unknown	1			
146	mutation	Exon 6	C-372>T	base substitution	p.Arg188X	missense (stop codon)	1		rs49486703	
83	mutation	Exon 6	C-381_382delinsT	complex	p.Lys177Asn183	truncating deletion	1			

Links to online databases

Links to variant-specific pages



2 Mutation Browser

Quick search

Nucleotide nomenclature (HGVS): Patient ID:

Protein nomenclature (HGVS): Family ID:

Advanced search

Variant information

Gene:

Variant ID:

Variant type:

Base change:

Protein change:

Control frequency:

Origin of variants:

Location:

Exon:

Nucleotide range:

Presence in public databases:

3 CEP290-related phenotypes

Links to corresponding phenotype sections

Fully customizable queries

Brain (MTS)

Kidney

Infantile NHP

Eye

Genotype-phenotype correlations in Joubert syndrome, megalencephaly and retinal degeneration

Overview of cilia genes in which mutations cause phenotypes characterized by megalencephaly, mild and/or subtle involvement of brain, blue and/or white matter, respectively pure Joubert syndrome (JS), isolated megalencephaly (MHP) and isolated retinal degeneration (IRD). Genes are arranged in order of increasing penetrance. LCA or Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) are also included. Underlines represent the multiplex phenotypes of JS blue retina, JS plus rod-cone dystrophy (rod-cone dystrophy (RCD)) and Senior-Lison syndrome (SLC). The most frequently mutated genes are underlined. From Mueller et al. and Seldin et al.

So far, there is no clear cut explanation for the extreme variability of the allelic spectrum of CEP290. At least two different theories are possible. On the one hand, it is presumed that the clinical variability is influenced by the mutational load at other genes encoding ciliary proteins. Another theory is disease modifying proteins that interact with CEP290 or function in the same pathway, might (indirectly) affect its function. On the other hand, certain (type of) mutations may differently affect the expression or behavior of CEP290.

4 Variant-specific page

c.3175dup (p.Ile1059AsnfsX11)

Variant ID:

Exon:

dbSNP ID:

OMIM:

Phenotypic features at different levels

Link to PubMed

Patient ID	Family ID	Gender	Age	Ethnicity	Origin	Surgically	Hereditary consanguinity	Consanguinity degree	Exon/Intron	Allele 1		Allele 2		Reference		
										Nucleotide nomenclature	Protein nomenclature	Nucleotide nomenclature	Protein nomenclature			
AL97 ID-1	AL97		35 y	Denmark	35 y retina unknown				Exon 29	3175-3176insA	p.I059X1069	Exon 55	7341-7342insA	L244892455	Sayer (2006)	
									Exon 28	c.3175insA	p.Ile1059AsnfsX10	Intron 26	c.3991+1655delG	p.Cys99X	DHPLC	Ferreault (2007)
									Exon 28	3167-3178insA	p.I059X1069	Exon 44	8668G>T	DHPLC	Braicoid (2007)	

1
2 The database is accessible from: <http://medgen.ugent.be/cep290base>. Information on variants can
3
4 be retrieved using the Mutation Overview (1) or the Mutation Browser (2). In addition, the
5
6 Phenotype page (3) describes all phenotypes associated with *CEP290* so far. The variant-specific
7
8 pages (4) are accessible from both the Mutation Overview and Mutation Browser and include
9
10 detailed information on the pathogenic potential. The database links to NetGene2 and BDGP for
11
12 splice site mutations and automatically fills in queries for PolyPhen and SIFT for missense
13
14 changes. In addition, the database includes variants in other genes that co-occur with *CEP290*
15
16 mutations, thereby providing a unique opportunity to link modifiers to associated clinical
17
18 manifestations.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 [Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG](#)
46 [translation initiation codon in the reference sequence \(NM_025114.3\), according to journal](#)
47 [guidelines \(www.hgvs.org/mutnomen\)](http://www.hgvs.org/mutnomen). The initiation codon is codon 1.

Page 2

Deleted: Table 1

Supp. Table S1: Overview of all *CEP290* mutations identified so far and their occurrence in different phenotypes.

Mutation		Associated phenotype								
Nucleotide nomenclature	Protein nomenclature	LCA	SLS	JS	JS + RD	JS + RF	CORS	MKS	MKS-like	BBS
c.1A>G	p.Met1?		1							
c.2T>A	p.Met1?	1								
c.21G>T	p.Trp7Cys		1				1			
c.103-13_103-18del	p.?						1			
c.164_167del	p.Thr55SerfsX3						1			
c.180+1G>T	p.?	1								
c.180+2T>A	p.?							2 (1)		
c.265dup	p.Thr89AsnfsX2	1								
c.287del	p.Asn96MetfsX29		1*		1*					
c.322C>T	p.Arg108X	1								
c.381_382delinsT	p.Lys127AsnfsX36							1		
c.384_385del	p.Asp128GlufsX17	1								
c.384_387del	p.Asp128GlufsX34	1						4 (2)		
c.437del	p.Glu146GlyfsX17	1								
c.451C>T	p.Arg151X	1								
c.566C>G	p.Ser189X	1								
c.613C>T	p.Arg205X							2 (1)		
c.679_680del	p.Glu227SerfsX2	1								
c.1066-1G>A	p.?						1			
c.1189+1G>A	p.?	1								
c.1219_1220del	p.Met407GlufsX14	3						1		
c.1260_1264del	p.Lys421GlyfsX2	2								
c.1361del	p.Gly454GlufsX5						1			
c.1419_1423del	p.Ile474ArgfsX5		1							
c.1550del	p.Leu517X	1								
c.1593C>A	p.Tyr531X	1								
c.1645C>T	p.Arg549X				1					
c.1666del	p.Ile556PhefsX17				1					

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_025114.3), according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Page 3

Mutation		Associated phenotype								
Nucleotide nomenclature	Protein nomenclature	LCA	SLS	JS	JS + RD	JS + RF	CORS	MKS	MKS-like	BBS
c.1682_1683del	p.Gln561ArgfsX14				1					
c.1709C>G	p.Ser570X	1								
c.1711+5A>G	p.?				1					
c.1824G>A	p.=	1								
c.1859_1862del	p.Arg621IlefsX2	2								
c.1860_1861del	p.Asp622PhefsX5							1		
c.1910-2A>C	p.?	1								
c.1936C>T	p.Gln646X	2 (1)								
c.1984C>T	p.Gln662X								2 (1)	
c.1992del	p.Pro665LeufsX10	1								
c.2118_2122dup	p.Thr709SerfsX9	1								
c.2218-15_2220del	p.?	1								
c.2218-4_2222del	p.?		2 (1)							
c.2218-2A>C	p.?	1								
c.2249T>G	p.Leu750X	1					1			
c.2251C>T	p.Arg751X						1			
c.2695C>T	p.Gln899X	1								
c.2906dup	p.Tyr969X								1	
c.2991+1655A>G	p.Cys998X	92 (83)								
c.3043G>T	p.Glu1015X								1	
c.3104-2A>G	p.?						1			
c.3104-1G>A	p.?								1	
c.3175del	p.Ile1059X								1	
c.3175dup	p.Ile1059AsnfsX11	1			1		1			
c.3176del	p.Ile1059LysfsX6						1			
c.3292G>T	p.Glu1098X	2								
c.3310-1G>C	p.?						1			
c.3310-1_3310delinsAA	p.?	3								
c.3422dup	p.Leu1141PhefsX5	1								
c.3793C>T	p.Gln1265X				1				1	

Deleted: c.2118_2122dup

... [1]

[Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence \(NM_025114.3\), according to journal guidelines \(www.hgvs.org/mutnomen\). The initiation codon is codon 1.](#)

Page 4

Mutation		Associated phenotype								
Nucleotide nomenclature	Protein nomenclature	LCA	SLS	JS	JS + RD	JS + RF	CORS	MKS	MKS-like	BBS
c.3811C>T	p.Arg1271X	1					4 (2)			
c.3814C>T	p.Arg1272X	1			1					
c.3922C>T	p.Gln1308X	1								
c.4001del	p.Thr1334IlefsX2	1								
c.4028del	p.Lys1343ArgfsX2	1								
c.4114_4115del	p.Ile1372LysfsX5	1								
c.4115_4116del	p.Ile1372LysfsX5	1						1		
c.4195-1G>A	p.?		1							
c.4393C>T	p.Arg1465X	1	2				3			
c.4656del	p.Glu1553LysfsX4						1			
c.4723A>T	p.Lys1575X	12	2		1		1			
c.4732G>T	p.Glu1578X				3 (1)					
c.4771C>T	p.Gln1591X						2 (1)			
c.4791_4794del	p.Lys1598SerfsX8						1			
c.4882C>T	p.Gln1628X	2			1*		3*			
c.4962_4963del	p.Glu1656AsnfsX3	2								
c.4965_4966del	p.Glu1656AsnfsX3						1			
c.4966G>T	p.Glu1656X	1								
c.5046del	p.Val1683X	1								
c.5163del	p.Thr1722GlnfsX2	3					2			
c.5226+1G>A	p.?	1								
c.5256_5257del	p.Ala1753ArgfsX7	2 (1)								
c.5344C>T	p.Arg1782X	1								
c.5434_5435del	p.Glu1812LysfsX5						1			
c.5493del	p.Ala1832ProfsX19	1					1	4 (2)		
c.5515_5518del	p.Glu1839LysfsX11						1			
c.5519_5537del	p.Lys1840ArgfsX5	1								
c.5587-1G>C	p.?	3			2					
c.5611_5614del	p.Gln1871ValfsX2				1*		1*			
c.5649dup	p.Leu1884ThrfsX23		1*		1*		3 (2)		2 (1)	
c.5668G>T	p.Gly1890X	2 (1)		1		3	9 (7)			

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_025114.3), according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Page 5

Mutation		Associated phenotype								
Nucleotide nomenclature	Protein nomenclature	LCA	SLS	JS	JS + RD	JS + RF	CORS	MKS	MKS-like	BBS
¥	p.Glu1903X					(2)				1
CEP290:c.5709+2352_54_C12orf50:c.290-1375_77del	p.?						1			
c.5722G>T	p.Glu1908X				1					
c.5734del	p.Trp1912GlyfsX11						4 (2)			
c.5776C>T	p.Arg1926X	1								
c.5813_5817del	p.Thr1938AsnfsX16	1								
c.5824C>T	p.Gln1942X			1*		1*				
c.5850del	p.Phe1950LeufsX15	3					2 (1)		2 (1)	
c.5865_5867delinsGG	p.Glu1956GlyfsX9	1								
c.5866G>T	p.Glu1956X	1								
c.5932C>T	p.Arg1978X		1							
c.5941G>T	p.Glu1981X						2			
c.6031C>T	p.Arg2011X				1					
c.6072C>A	p.Tyr2024X						2 (1)			
c.6271-8T>G	p.?						1			
c.6277del	p.Val2093SerfsX4						1			
c.6331C>T	p.Gln2111X						1			
c.6604del	p.Ile2202LeufsX24	7 (2)								
c.6869del	p.Asn2290IlefsX11						2			
c.6870del	p.Gln2291LysfsX10						2 (1)			
c.7318_7321dup	p.Leu2441SerfsX16						2 (1)			
c.7341dup	p.Leu2448ThrfsX8	1			2					
c.7366_7369del	p.Thr2457AlafsX27				2 (1)					
Total number of distinct patients (families)		184 (167)	13 (12)	2	23 (20)	-4 (-3)	-65 (-53)	-17 (-11)	-10 (-7)	1

Deleted: 1

Deleted: 22

Deleted: 19

This table gives an overview of the number of patients carrying a specific mutation, for each phenotype (updating date: 14th of June, 2010). Numbers between brackets indicate the unique

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_025114.3), according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Page 6

1
2 number of families. Abbreviations used: LCA: Leber Congenital Amaurosis; SLS: Senior-Loken
3
4 syndrome; JS: Joubert syndrome; JS + RD: Joubert syndrome with associated retinopathy; JS +
5
6 RF: Joubert syndrome with associated renal failure; CORS: cerebello-oculo-renal syndrome;
7
8 MKS: Meckel-Grüber syndrome; MKS-like: Meckel-Grüber syndrome-like; BBS: Bardet-Biedl
9
10 syndrome. †: nucleotide nomenclature not specified in publication. *: both patients carrying the
11
12 mutation belong to the same family.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Deleted:

Deleted: -

For Peer Review

[Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence \(NM_025114.3\), according to journal guidelines \(www.hgvs.org/mutnomen\). The initiation codon is codon 1.](#)

Page 7

Deleted: Table 2

Supp. Table S2: Overview of all *CEP290* unclassified variants identified so far and their occurrence in different phenotypes.

Unclassified variant		Associated phenotype			
Nucleotide nomenclature	Protein nomenclature	LCA	NPHP	JS +RF	Healthy
c.1991A>G	p.Asp664Gly			1	1
c.2717T>G	p.Leu906Trp				1
c.6684T>G	p.Asn2228Lys				1
c.4696G>C	p.Ala1566Pro	1			
c.5081T>C	p.Leu1694Pro	1			
c.4661_4663del	p.Glu1554del	1			
c.7311_7313del	p.Lys2437del		1		

Abbreviations used: LCA: Leber Congenital Amaurosis; NPHP: nephronophthisis; JS + RF:

Joubert syndrome with associated renal failure.

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_025114.3), according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Page 8

Page 4: [1] Deleted		Frauke Coppieters			6/14/2010 5:55:00 PM				
c.2118_2122dup	p.Thr709SerfsX9	1							

For Peer Review

Unable to Convert Image

The dimensions of this image (in pixels) are too large to be converted. For this image to convert, the total number of pixels (height x width) must be less than 40,000,000 (40 megapixels).

Supp. Figure S1: Overview of CEP290base.

The database is accessible from: <http://medgen.ugent.be/cep290base>. Information on variants can be retrieved using the Mutation Overview (1) or the Mutation Browser (2). In addition, the Phenotype page (3) describes all phenotypes associated with *CEP290* so far. The variant-specific pages (4) are accessible from both the Mutation Overview and Mutation Browser and include detailed information on the pathogenic potential. The database links to NetGene2 and BDGP for splice site mutations and automatically fills in queries for PolyPhen and SIFT for missense changes. In addition, the database includes variants in other genes that co-occur with *CEP290* mutations, thereby providing a unique opportunity to link modifiers to associated clinical manifestations.